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Abstract

Title of Dissertation: Drug Delivery Strategies using Light Sensitive Molecules
By Martin Michael Dcona, M.Sc
A thesis submitted in partial fulfillment of the requirements for the degree Doctor of
Philosophy, in Chemistry at Virginia Commonwealth University, 2012.
Major Director: Matthew C. T. Hartman, Ph.D., Assistant Professor, Dept. of
Chemistry, VCU
Cancer remains one of the most dreaded diseases due to inevitable suffering and possible
fatality. Only cardiac disease has caused more deaths than cancer1. Present day cancer
treatment involves radiation, surgery or chemotherapy. In chemotherapy, an anti-tumoral
drug is used to treat the tumor either by killing or stalling the growth of the tumor cells.
In certain types of cancer, for e.g. metastatic breast cancer, the first line of therapy is
often chemotherapy. But the inability of current clinically approved drugs to selectively
target tumor cells, ultimately results in side effects. To reduce these side effects, prodrug
therapies have been developed. A prodrug is defined as a drug molecule inactivated by a
temporary cap or carrier, subsequently removed by an external intra or extracellular
stimulus. Several prodrug strategies such as ADEPT (Antibody–Directed Enzyme
Prodrug Therapy) 2 have been tested in clinical trials but have thus far met with limited
success.
In the wake of these limitations, development of photo-activatable prodrugs may be
particularly desirable for minimizing the adverse side effects associated with current

xvii

cancer chemotherapeutics. Photodynamic therapy (PDT)3 is a light dependent tumor
treatment modality that has existed for many years. PDT involves a photosensitizer which
is administered to the patient and later activated using the light of wavelengths between
650-800 nm. The activated photosensitizer creates singlet oxygen, which acts as
cytotoxic agent to the tumor cells. But this approach has several drawbacks including
slow uptake of the photosensitizer by the tumor cells and the dependence on molecular
oxygen that is not always present at even moderate levels in the tumor tissues.
To address these limitations of PDT, we developed a new prodrug concept called
‘Photocaged Permeability’ in our first project, and demonstrated drug delivery using this
approach 4. The basis of this concept is that, by attaching a hydrophilic molecule to the
drug via a photosensitive linker, the permeability of the drug could be restrained. But the
drug could be released at the site of the tumor after irradiating with UV light. To achieve
this goal, we designed and synthesized a photosensitive drug conjugate that was
comprised of doxorubicin attached to a negatively charged, cell impermeable molecule,
EDANS (5-((2-Aminoethyl) amino) naphthalein-1-sulfonic acid) via a photosensitive
nitroveratryl linker. Later, we performed MTT (cell viability) assays using esophageal
adenocarcinoma (JH-EsoAd1) cells to determine the efficiency of our drug conjugate to
induce cell death. As expected our drug conjugate was able to induce cell death, but only
in presence of light. But in the dark, the cells remained unaffected. Also, we did several
control studies to substantiate the fact that the cell death was actually due to drug release
but not due to light or other entities. Further, we performed FACS (Fluorescence Assisted
Cell Sorting) and confocal assays to show that in dark, the drug conjugate did not

xviii

permeate cells. But upon irradiation with UV light, the drug was released from the
conjugate, permeated the cells and induced cell death.
A weakness of the above mentioned approach is that the drug is “decaged” or photoreleased from the conjugates only under UV light; which cannot be translated to
physiological conditions. This is because the UV light cannot penetrate deeper than 5 mm
into the human skin5. As a result, tumor cells that are deeply embedded in the human
body cannot be treated using these approaches. To address this problem, Near Infrared
(NIR) light could be used as it penetrates deeper than UV. Recently, several groups have
reported using Upconverting Nanoparticles (UCNP) 6 for the purpose of drug activation.
The basis of this phenomenon is that the incidence of NIR light on these particles initiates
multi-photon processes, eventually emitting UV/VIS wavelengths. The advantage of the
NIR is that it deeply penetrates into the human skin. In our latest project, we have
designed a drug conjugate that would be attached to UCNPs. We envision that after
grafting the drug conjugate onto the nanoparticles and irradiating it with NIR drug release
will occur as a result of upconversion.
The above two systems describes novel methodologies for controlled release of the drug.
To further improve the efficacy of the drug action, we designed new photosensitive
systems based on the concept of targeted drug delivery. Targeted drug delivery is a
treatment methodology in which the modified chemotherapeutic drug with higher tumor
affinity could be concentrated in the tumor tissues. In certain cases, the receptors of
tumor cells are targeted for the purpose of therapy. Receptors are cell surface proteins
that are expressed on their plasma membrane. A select few of them such as Folic Acid
Receptor (FAR)
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and PSMA (Prostate Specific Membrane Antigen) 8are overexpressed

xix

in malignant cells. In our new designs, we attached folic acid9 and urea based (DUPA)
ligand10, which were previously reported to bind to FAR and PSMA receptors
respectively. Cell studies are currently underway to determine the specificity of these
drug conjugates in targeting tumor cells.
Once we demonstrate the above drug delivery strategies in vitro and later in vivo, we will
have established novel drug delivery systems that could potentially be applied towards
chemotherapeutic treatment.
References:
1. http://www.cdc.gov/nchs/fastats/lcod.htm
2. I. Niculescu-Duvaz, C.J. Springer. Antibody-directed enzyme prodrug therapy
(ADEPT): a review Adv. Drug Deliv. Rev. 26, 151–172
3. I. J. Macdonald and T. J. Dougherty. Basic principles of photodynamic therapy. J.
Porphyrins Phthalocyanines 2001, 5, 105–129
4. M. M. Dcona, D. Mitra, R.W. Goehe, D. A. Gewirtz, D.A. Lebman and M.C. T.
Hartman. Photocaged permeability: a new strategy for controlled drug release. Chem.
Commun., 48, 4755-4757
5. M. Meinhardt, R. Krebs, A. Anders, U. Heinrich, H. Tronnier. Wavelength-dependent
penetration depths of ultraviolet radiation in human skin. J. Biomed. Opt. 13, 044030.
6. N. M. Idris, M. K. Gnanasammandhan, J. Zhang, P.C Ho, R. Mahendran, Y. Zhang. In
vivo photodynamic therapy using upconversion nanoparticles as remote-controlled
nanotransducers. Nat. Med. 18, 1580–1585.
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CHAPTER 1: CANCER AND CHEMOTHERAPY

2

1.1 Cancer
Cancer remains one of the most dreaded diseases in the modern world. According to
the latest statistics1, it remains the second highest cause of deaths that occur in the
United States of America. The most common form of cancer in the male population is
prostate cancer and in females, breast cancer. The disease is usually characterized by
uncontrolled growth of cells that are naturally supposed to undergo apoptosis. But
instead they proliferate and form tumors. In some cases, these abnormal cells
metastasize and ultimately result in the death of a patient. The causes of cancer are
usually attributed to external factors such as tobacco, radiation etc. or internal factors
such as mutation, obesity etc. In all cases, there are consequential formations of
abnormal cells. Common treatments for cancer include radiation therapy, surgery,
chemotherapy etc.
Chemotherapy
Chemotherapy is a common methodology in cancer treatment. It usually involves
antineoplastic drugs that are administered either singly or in combination. These
drugs act on the abnormal cells and kill them typically by interfering with DNA
synthesis2. A key issue associated with conventional chemotherapy is unfavorable
bio-distribution of the drug and low levels of drug accumulation in the tumor tissue.
As a result current chemotherapies exhibit inevitable side effects.
1.2 Passive Targeted Drug Delivery
To regulate the side effects caused due to non-specific activity of the drug conjugate,
targeted drug delivery was developed. Targeted drug delivery refers to drug
accumulation at a particular site, specifically within the tumors via receptors or
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growth factors. In this section, a few examples of targeted drug delivery will be
illustrated.
Principles of drug delivery:
Drug transportation to a tumor site relies on two basic targeting approaches. They are
active and passive targeting.
Passive Targeting and ‘Enhanced Permeation and Retention’ effect
Passive targeting refers to drug accumulation in tumor tissues with leaky
vasculatures. The endothelium is made of tightly packed cells. But in case of tumors,
the tight packing of cells is disrupted, which eventually develops leaky vasculature
which can allow small and large molecules easily to penetrate through the tissues (Fig
1.2.1). Hence, this characteristic of tumor tissues was used to improve the
permeability and concentration of the drug molecules in chemotherapy. This
approach is referred to as Enhanced Permeation and Retention (EPR) effect3. Drug
delivery via conventionally used liposomes is an example of passive targeting.
Liposome mediated drug delivery
Liposomes are a micro-particulate assembly of amphiphilic molecules that are
spontaneously formed when lipids are hydrated in aqueous media4. The liposomes are
used to encapsulate drug molecules and hence, they are used as drug carriers. (Fig.
1.2.2)

4

Fig. 1.2.1 Passive Targeting: Graphical representation of normal and tumor tissue with
respect to vascular permeability of small and large drug molecules

5

Lipid Bilayer

Cell surface receptor
binding small molecule,
antibody and peptide

Drug

Fig. 1.2.2 Drug encapsulated in liposomes.
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In ‘passive’ liposome mediated drug delivery, a therapeutic molecule that is either
hydrophilic or hydrophobic is encapsulated in a lipid bilayer with aqueous phase.
This particle when administered to the patient will penetrate leaky tumor vasculature
due to the EPR effect. Examples of passive targeted liposomes that are currently used
in chemotherapy are Doxil5, Myocet6 etc. But, passive targeting of liposomes suffers
from a major disadvantage of non-specific localization7. To address this issue, cell
surface receptor binding ligands were attached to the surface of liposome for
enhanced specificity leading to ‘active’ liposome mediated drug delivery.
1.3. Active Targeting: Targeting receptors on tumor cells
1. 3. 1. Introduction:
A major challenge with current chemotherapy is off-target toxicity which leads to
significant side effects. Here, we highlight the importance of targeted drug delivery and
describe several targeted delivery strategies.
Targeted drug delivery:
To reduce off-target effects of anticancer drugs, targeted drug delivery has been
developed. This type of drug administration refers to predominant drug accumulation in
tumor cells via usage of a homing ligand or a peptide that binds specifically to a receptor
expressed primarily on cancer cells.
Human cell surface receptors are proteins that are predominantly expressed on plasma
membranes. These receptors exhibit high affinity towards certain types of vitamins and
nutrients required for the proper growth of cells. But in malignant cells, these receptors
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are overexpressed due to abnormal functioning of cellular mechanisms. And when these
ligands are modified by conjugating a therapeutic drug, they enhance the concentration of
the non-selective drug specifically in the tumor cells, limiting off target side effects. As a
result these receptors are becoming increasingly popular for the purpose of
chemotherapy11 and are also being used towards imaging12.
Targeted delivery often employs a ligand that binds to the receptors that are
overexpressed on the cell surface, with high specificity and affinity. Such targeting
ligands include folic acid13, LHRH14 etc. There are also certain small molecular weight
inhibitors that bind to overexpressed cell surface proteins such as 2-PMPA12. In this
section, we highlight two different ligands and their targets that embody all the above
features. Specifically, we will be describing folate receptor and Prostate Specific
Membrane Antigen (PSMA) receptor mediated drug delivery.
1. 3. 2. Receptor mediated Endocytosis:
Endocytosis refers to a pathway by which a molecule is carried into cells via membrane
invagination and internalization15. Receptor mediated endocytosis occurs via cell surface
proteins that interact with the exogenous ligands and mediate their passage into the cells.
Many examples of cell surface proteins exist which are overexpressed in tumors. Some of
the best established include Folate Receptors (FR)

11

, PSMA16 and Growth Factor

Receptors such as vascular endothelial growth factor (VEGF) Receptors17.
Mechanisms of Endocytosis:
There are several types of endocytosis pathways18 which include: Clathrin-mediated
endocytosis, non-clathrin or caveolae mediated endocytosis, macropinocytosis and
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phagocytosis15. But here, we will focus on the first two as they are of primary concern in
our work.
Clathrin Mediated Endocytosis (CME):
CME is the most common form of endocytosis and is responsible for internalization of
ligands, antigens etc. Clathrin is a protein that plays an important role in formation of
vesicles19. The internalization of the incoming ligand takes place by recruitment of
soluble clathrin from the cytoplasm to the cell membrane. The multi-protein interactions
then result in formation of clathrin coated pits that bud from the cellular membrane.
These pits then internalize forming vesicles that encapsulate the incoming ligand or
antibody via receptor. Later these encapsulated vesicles are pinched-off from the plasma
membrane and continue to move into cytoplasm to form an early endosome and then late
endosomes. Finally, these late endosomes merge into lysosomes that contain low pH
enzymes. At this point, the ligand binding receptor either gets destroyed or recycles back
to the cell surface for additional rounds of internalization (Fig. 1). An example of clathrin
mediated endocytosis is the internalization of PSMA16.
Caveolae mediated or Clathrin independent Endocytosis (CIE):
In caveolae mediated endocytosis, the buds that are generated from the plasma membrane
are not coated with clathrin; hence it is most commonly referred to as Clathrin
independent endocytosis. Caveolae are cholesterol- and glycosphingolipid-rich flask
shaped invaginations of the plasma membrane that are abundant in vascular
endotheliums. The mechanism of CIE is similar to the CME, wherein multi-protein
interaction results in formation of a cave like structure. These “small caves” shaped pits
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(hence the name), are responsible for endocytosis of certain ligands such as folic acid 13,
and several nonenveloped viruses19.
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Caveolae or clathrin independent
endocytosis

Clathrin mediated endocytosis

Dynamin
(pinches off
pits from
membrane)

Non-coated pits
Recycling
endosomes

Clathrin coated
pits
Caveosomes

Clathrin
uncoating from
vesicles

Clathrin
Early
endosomes

Late
endosomes
Fig. 1. 3. 1: Clathrin and Caveolae mediated endocytosis

Lysosomes

Drug
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1. 3. 3. Folate receptor mediated drug delivery
Folic acid (FA), also known as vitamin B9, is taken up by cells and is metabolized to
tetrahydrofolate and other reduced FA derivatives which are the substrates for many
important enzymes in the cell20. FA is needed to carry one carbon for methylation
reactions and de novo synthesis of nucleotide bases. Therefore, it is essential to the
viability of proliferating cells11.
Cellular uptake of Folic acid
In the human body, two independent and mechanistically different systems mediate the
cellular uptake of FA.


The Reduced Folate Carrier (RFC) is a low affinity (Kd ~ 10-5 M), high-capacity
membrane-spanning anion transport protein that delivers reduced FAs across the
plasma membrane in a bidirectional fashion21.



The Folate Receptor (FR) is a high affinity (Kd ~ 10-10 M), single chain FAbinding protein which internalizes FA through active-receptor mediated
endocytosis13.

Isoforms of FRs
There are three known isoforms of the folate receptor. Specifically, FR-α and FR-β are
the isoforms that are associated with cell membrane and, FR-γ and its truncated cogener
FR-γ’, are the secreted from.13 In healthy human tissue, FR-α is limited to the apical
(externally-facing) membrane of the polarized epithelial cells, thus it is not accessible to
folates in the blood stream. For this very reason, normal tissues are not affected by the
folate receptor mediated therapy, making this approach very selective22. Whereas, in
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malignant cells, the FR (α) isoforms of the folate receptor are highly overexpressed 23 and
hence serve to target drug delivery to those cells.
Folic acid conjugates:
Folic acid (Fig. 1.3. 2) has two components, pteroic acid and L-glutamic acid which are
coupled via a peptide bond. Conjugation of molecules to FA at its γ-carboxy moiety on
glutamic acid may influence its binding affinity towards FR. However, it was found in
many cases, that this conjugation does not affect the Kd value significantly, and thus this
site is commonly used for derivatization.
An example of the effectiveness of FA targeting can be demonstrated by examining the
bio-distribution of

111

In –diethylene triamine pentaacetic acid (DTPA) - FA, an imaging

agent in patients that are tumor free and those that possess FR-positive tumors (Fig 3). In
a healthy individual, accumulation of the conjugate is only seen in the kidneys. But in the
patient with the metastasizing cancer, the imaging probe binds to the tissues that
overexpress the FR and thus FR positive tumors are evident throughout the body, as seen
in scintigraphic images24.

13

Pteroic acid

L-Glutamic acid

Fig. 1.3.2. Chemical structure of folic acid
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Fig. 1. 3. 3. Chemical structure of

111

In–DTPA–folate used in whole body scintigraphic

images cancer patient. The uptake of this molecule in the cancer patient is seen only in
the malignant tissue
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Folate receptor mediated endocytosis of drug conjugate:
As mentioned previously, folic acid and folate conjugates undergo FR mediated
endocytosis.

The events that occur during folate receptor-mediated endocytosis are

illustrated in Fig 1. 3. 4.
Mechanism:
At first exogenous folic acid binds to receptors that are continuously recycling and are
exhibited on the cell surface. After binding, the plasma membrane begins to invaginate
until a distinct vesicle called an early endosome (shown in yellow) forms within the cells.
These vesicles with ligand and receptor may interact with golgi apparatus, which are then
transported to late endosomes. At this point, the pH value in these vesicles lowers to ~ 5
through the action of proton pumps, after which the ligand dissociates from the receptor.
After this, one of the below listed events may occur25.


The ligand and the receptor may end up in the lysosomes for destruction26



The ligand may be directed to lysosome for destruction whereas the receptor may
recycle back to cell surface



The ligand can leak into the cytosol (this is the case with folic acid and its
receptor recycling)



Both ligand and receptor recycle back to the cell surface
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Fig. 1. 3. 4. Folate receptor mediated endocytosis of folic acid-drug conjugate
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Example of Folic acid-drug conjugate used in clinical trials:

Folic acid

EC145

.
Vinblastine

Fig: 1. 3. 5. Vintafolide (EC145) is a vinblastine conjugate linked to folic acid (JCO, 2012,
4011-4016)
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1. 3. 4. PSMA binding ligands
Rationale
PSMA is highly homologous to the enzymes that are found in the central nervous system
(CNS) and proximal small intestines27. One of the enzymes in the CNS is the
neuropeptidase NAALDase, which releases the neurotransmitter glutamate which were
found to be responsible in number of neurological disorders28. Hence to reduce these
disorders NAALDase/GCP II inhibitors were developed; which were also found to be
potential PSMA inhibitors.
Phosphonate based inhibitors:
One of the first reports of the NAALDase inhibitor was published by Jackson et al
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wherein they reported synthesis of phosphonate and phosphinate inhibitors. In this work
they found that 2–(phosphonomethyl)-pentanedioic acid (2-PMPA) had over 1000 times
more potency (Ki= 0.275 nM) than other conventional inhibitors30, 31 However, 2-PMPA
suffers from a poor pharmacokinetic profile due to its high polarity, so its value as a
therapeutic drug has been limited.
Urea based inhibitors:
Later, Kozikowski et al32 reported urea based inhibitors, based on the mechanism of the
enzyme as well as modeling studies. These inhibitors comprised of two amino acids that
are joined through a urea bond. Unlike 2-PMPA, the synthesis of these molecules is
easier and could be modified to attach a drug or an imaging agent. Also the binding
efficiency (Ki= 0.8-8.0 nM) of these molecules is almost equal to that of 2-PMPA.

19

Fig. 1. 3. 6: Phosphonate and urea based inhibitors with their respective Ki values.
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Applications of PSMA binding ligands
PSMA in Imaging:
Recently, several groups have demonstrated successful usage of PSMA inhibitors for
imaging in experimental models of prostate cancer12, 16. This was done by conjugating
radio-nuclides to the above discussed urea and phosphinate based inhibitors. A general
example of an imaging molecule is shown in Fig. 1.3.6.

Fig. 1. 3. 7: A general example of an imaging molecule for PSMA imaging
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PSMA in Therapy:
PSMA has served as an ideal target for several monoclonal antibodies that are highly
specific in treating prostate cancer. But the usage of the PSMA binding ligands for the
purpose of treatment is relatively new and has not yet been explored in clinical trials. One
of the first examples of application of targeted therapy in vivo was demonstrated by Phil
Low and group, wherein they were able to demonstrate the specificity of the urea based
ligands towards PSMA for the purpose of drug delivery16.
1.3.5 Antibody Directed Enzyme Prodrug Therapy (ADEPT):
A final example of active targeting is ADEPT9. In this methodology an enzyme (E) is
conjugated to an anti-tumor antibody and is administered to the patient. The enzymeantibody conjugate recognizes the tumor specific-antigen and hence localizes inside the
tumor tissues. Later, a prodrug is administered to the patient, which is converted to an
active cytotoxic drug by the enzyme that is now present only inside the tumor (Fig.
1.3.8)10.

22

Fig. 1.3.8 Graphical description of ADEPT
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1. 3. 6. Disadvantages of receptor targeted drug delivery:
Traditional tumor therapies suffer from non-specificity of drug retention and action,
resulting in toxicity to healthy tissues. In wake of this limitation, the advantage of
targeting receptors to be able to deliver the anti-cancer drug specifically to the tumor cells
has opened a new avenue to develop novel targeted therapeutics with reduced side
effects. As mentioned many times in this chapter, receptor mediated drug delivery
employs a ligand conjugated to a drug molecule, which then selectively binds to tumor
receptors, undergoes endocytosis and eventually releases the cytotoxic drug. However,
the therapeutic application of receptor-drug conjugates in biological environments suffers
from some key problems. Firstly, the endocytic pathways transport only a fraction of the
drug conjugates into cells. As a result, the optimum levels of drug concentration required
for cell death may not always be present. The other limitation is endosomal entrapment of
the drug conjugate. Once internalized, the drug conjugate can be trapped inside the
endosomes, resulting in accumulation of latent drug conjugate. This is more common if
the drug conjugates are membrane impermeable.
Alternative to the existing drug delivery system:
In wake these limitations, a modified ligand-drug conjugate is essential that can
overcome most of the above drawbacks. As mentioned in the previous section, light
sensitive molecules have been previously applied toward drug delivery. Hence, to allow
the easy endosomal escape of the drug, it is desirable to design an easily activatable drug
conjugate. In chapter 3, we report two such drug conjugates combining the merits of
targeted drug delivery and photocaged drug delivery.
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Chapter 1.4: Photodynamic Therapy: The emergence of light based therapy
1.4.1 Introduction
The usage of light for therapeutic purposes has seen a great surge since the introduction
of Photodynamic Therapy (PDT) as a non-invasive, yet effective treatment modality. In
Photodynamic therapy a combination of low energy light, photosensitizer and tissue
oxygen is employed to induce cell death. The success of this treatment depends on
generation of singlet oxygen, which is the main cause of cytotoxicity. PDT has been
employed in many malignant diseases with some success33.
In this section, the mechanism of PDT and disadvantages associated with this treatment
modality will be discussed.
1.4.2. Mechanism of PDT:
In PDT, a porphyrin based unit called Photosensitizer (PS) is employed in conjunction
with light of wavelength between 600-800 nm. In clinical treatment, PDT is two-step
process. Firstly, a PS is administered to the patient either intravenously or topically at the
site of tumor. After a certain period of time, the photosensitizer is allowed to clear from
the body, but retained in tumor tissues, the skin and endothelial systems34. In the second
step, the tumor is irradiated with light of an appropriate wavelength (depends on PS used)
usually with laser or LED light source. As a result, the PS gets activated to form P* (high
energy PS), which eventually results in number of photochemical reactions. These
reactions result in generation of cytotoxic ROS (reactive oxygen species), predominantly
singlet oxygen (1O2) from oxygen in the environment of tissues. This specie oxidizes the
bio-molecules in the cells eventually leading to cell death35.
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Time lapse

Step1: Photosensitizer
(PS) is injected to the
patient

Step 2: After certain
time interval, PS
accumulates in tumor;
later irradiated with
λ=650-800 nm light
Fig.1.4.1 Mechanism of Photodynamic Therapy

Tumor cells are killed
due to generation of
singlet oxygen species:
Seen here is the
decreased tumor
volume
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1.4.3 Photosensitizer:
The efficiency of PDT is dependent on three important components. 1) Photosensitizer 2)
Intensity and location of light treatment 3) Molecular oxygen.
The majority of PSs that are currently being used in research and clinical trials are
derivatives of porphyrin units. These cyclic units have good photophysical and
photosensitizing properties and are able to selectively accumulate in tumor tissues33. The
preferential retention of a PS in tumor is attributed to presence of leaky vasculature34. PSs
can be modified by attaching ligand36, antibody37 or peptides38 to increase their
concentration in tumors.

27

Fig. 1.4. 2. Chemical structures of some clinically used photosensitizers
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1.4. 4 Limitations of PDT:
Although PDT has great potential as a cancer treatment modality, there are several
drawbacks that limit its applicability in clinical therapy. One of them is unpredictable
light to drug administration times caused by slow uptake/ metabolism of the
photosensitizers

39

.

One of the major drawbacks of PDT is that the most commonly used

photosensitizers absorb light between 630-690 nm40 which has very low tissue
penetrability. This is due to the fact that there is absorption and scattering of the incident
light. The other major drawback of this therapy is dependence on molecular oxygen,
which is required to create singlet oxygen in presence of PS. Tumor tissues don’t always
have moderate levels of oxygen in their surroundings, due to which this treatment
modality may be unsuccessful41.
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1.5. Photo-responsive Molecules: Focus on O-nitroveratryl photocage
Introduction
Recently, light mediated biological processes have gained great attention due to the fact
that light offers a high level of spatial and temporal control. In this section, we illustrate
two different types of light sensitive molecules that are currently being used for certain
biological and drug delivery systems.
1.5.1. Photoswitches:
Photoswitches belong to the class of photo-responsive molecules that undergo
conformational change under the irradiation of light42. Most of the currently used
photoswitches are responsive towards UV light and undergo structural isomerization as a
result of multi-electron phenomena. Several examples of photoswitches are
azobenzenes4, spiropyran/merocyanine43, fulgides42 and hemothioindigo44 chromophores.
(Fig.1.5.1). Azobenzenes45 are the most common form of photoswitches that have been
used for many applications in materials46 and biological chemistry47. Their usefulness
stems from the fact that they undergo reversible photoswitching from trans to cis of the
N=N, under UVA light, specifically ~360 nm and then undergo thermal relaxation, in
dark or at 450 nm. The time required for thermal relaxation depends on the modification
on the azobenzene or on the biomolecule to which it is conjugated48.
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Fig. 1.5.1 Photoswitches: a) Azobenzenes b) Spiropyrans c) Hemothioindigo d) Fulgides
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1.5.2. Photocages:
Introduction
Photosensitive protecting groups are often referred to as “photocaging” molecules or
simply “photocages”. Photocaging refers to a phenomenon wherein the activity of a
certain molecule is blocked using a photosensitive linker that can be removed at a later
time when this molecule is irradiated with light of an appropriate wavelength; thus,
restoring its activity42, 49. This phenomenon is called “decaging”. One the first examples
of application of photocages dates back to 1978, when Kaplan et al50 used photocaged
caged ATP compounds for studying Na/K pump. Since then many groups51-53 have
installed photocaging groups onto biomolecules to modulate their activities with spatial
and temporal control.
Examples of photocaging molecules:
Many photocaging molecules have been developed for a number of biologically relevant
functional groups such as phosphates54, amines55 and thiols56. These molecules undergo
rapid irreversible photolysis under light of the appropriate wavelength, but are stable in
dark conditions. In this section, we describe three of the most commonly used photocage
molecules that are activated at different wavelengths and describe their applicability in
current research.
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O-Nitrobenzyl derivative

Coumarinyl derivative

Cob-4 derivative

Fig: 1.5.2 Photocage Molecules
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1.5.3. O-nitrobenzyl caging group:
One of the most commonly used photocage molecules is the o-nitrobenzyl (ONB) 57 and
its derivatives (1.11-1.14). The reason for vast applicability of these molecules is that
they can be easily installed on any functional group including amines, thiols, alcohols or
carboxylates. As a result, they have been applied to nucleic acids58, proteins59, peptides60
and small molecules61. These molecules could be activated at wavelengths ranging from
315-400 nm depending on the functional groups on the core molecule57. In addition, the
release kinetics of these molecules are extremely fast in comparison to any other caging
units. These molecules undergo photolysis at a rate of micro to milliseconds and give
quantitative yields.
But there are also several key disadvantages of using the ONB group as a photocage.
Primarily, these molecules are decaged only in presence of near UV, which might be
detrimental toward cells62, especially in cases where longer exposure of light is needed
for performing the in vitro assays. Although many findings indicate that ONB could be
applied toward chemotherapy, the major drawback of this approach is the range of
wavelength that is being employed for decaging is less penetrating rendering this
approach ineligible for in vivo studies.
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Mechanism of deprotection of ONB63:
Deprotection of ONB occurs under UV light. The reaction begins with the creation of
excited state singlet radicals on oxygen and nitrogen of the ‘nitro’ functional group. The
reaction then proceeds with 1, 5 transfer of hydrogen from carbon to oxygen, a Norrish
type II process which is promoted by the greater strength of the O-H bond compared to
the C-H bond, to give a Z-nitronic acid intermediate. Later the –OH attacks the methide
to form an unstable five membered ring. Then charge transfer from oxygen results in
formation of nitroketone or nitrosoaldehyde depending on the initial derivative of ONB
and release of the photocaged molecule (X) (Fig. 1.5.3).
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X= Biomolecule/
Drug

Fig. 1.5.3: Mechanism of photo release from ONB caging unit
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Examples of ONB caged compounds:
In this section, certain representative examples that use ONB as a photocage for different
molecules are illustrated.
Photocaged Nucleotides:
Deiters and group recently demonstrated an example of ONB derivatized, caged
oligonucleotides (Fig. 1.5.4 a). Specifically, they caged thymidine nucleotides which are
part of Triplex Forming Oligonucleotides (TFO) that help to regulate gene expression by
inhibiting transcription. Due to caging, the formation of TFO: DNA triplex formation is
blocked, hence rendering the TFO inactive. But under UV, thymidine nucleotides are
decaged hence leading to the inhibition of transcription58.
Photocaged Proteins
Schultz and coworkers reported the usage of ONB in a photocaged tyrosine amino acid
(Fig. 1.5.4 b), which was genetically encoded in E. coli. Incorporation of this caged
molecule into a cytoplasmic enzyme, β-galactosidase; rendered it inactive. But under the
irradiation of UV light, the ONB group was removed, which restored the activity of the
molecules59.
Photocaged Small Molecules
Recently, Mascarenas and group reported the ONB derivatized nucleic acid stains such as
ethidium bromide (Fig. 1.5.4 c) and DAPI. Using these caged molecules, they were able
to demonstrate their inability to selectively bind DNA molecules. But under the
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irradiation of UV light, the binding abilities were restored and were able to stain living
cells and retinal tissues61.

Fig. 1.5.4: Examples of ONB caged molecules
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1.5.4. Coumarin caging group
Coumarin derivatives are less commonly used caging molecules but their application as a
photocage has several key advantages. One of the most important advantages of this
molecule over ONB is that it is activated in light of wavelength above 400 nm. This
wavelength is not as damaging to the biomolecules as is UV. In addition, coumarinyl
derivatives are fluorescent in nature to an extent. But when they undergo
photoconversion the fluorescence of the molecule can be enhanced up to 200 fold64.
Example of coumarin caged compounds
Wiesner and coworkers65 used a coumarinyl methyl ester for caging cyclic nucleotides to
study spatiotemporal dynamics of nucleotide dependent processes using one photon and
two photon processes. Using this caged cNMPs, the authors were able to demonstrate
spatial and time dependent control over cNMP triggered processes.

Fig. 1.5.5: Example of photo release of cNMP from coumarin caged unit
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1.5.5. Cob-4 cage molecule
Very recently, Lawrence and coworkers introduced a photocage (1.18) that could be
cleaved in the range of 560 nm. In this seminal work, they reported vitamin B12 (cob-4)
as a photocage and described its application towards site selective photodecaging at
higher wavelengths which were never described previously. Specifically, cob-4 along
with O-nitrobenzyl and coumarin units--each conjugated to different fluorescent
molecules--were incubated with cells and irradiated at different wavelengths (Figure
1.5.6) that are specific for the different photo-protecting groups66.

Coumarin

Coumarin
Cob-4

O-Nitrobenzyl

560
nm

O-Nitrobenzyl

440
nm

360 nm

O-Nitrobenzyl

1.5. 6. Wavelength selective photolysis of cob-4, coumarin and ortho –nitro benzyl units
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Abstract:
Light is used to release a drug from a cell impermeable small molecule, uncloaking its
cytotoxic effect on cancer cells.
2. 1. Introduction:
Off-target toxicity plagues conventional cancer chemotherapy. One strategy to enhance
selectivity of anti-cancer drugs involves unmasking the cytotoxicity of a molecule in the
vicinity of the tumor.1 This type of activation can be mediated by enzymes,2,3 changes in
pH,4 or exogenous factors such as temperature5 or light.6–8
Light is an ideal external stimulus since it provides a broad range of adjustable
parameters9 that can be optimized for biological compliance. Several approaches that use
light for biomolecular activation have been reported.10–15 One established method to
enable selectivity of drug action using light is photodynamic therapy (PDT). In
PDT,16,17 light activation of a photosensitizer generates cytotoxic singlet oxygen killing
only illuminated cells. PDT is currently used in several types of malignancies16 including
skin, lung, esophageal, bladder, head and neck, and prostate cancer. A related strategy,
photochemical internalization,18,19 also uses photosensitizers. In this case, the
photosensitizers are used to release macromolecular cytotoxins from endosomes,
enabling their entry into the cytosol. However, these approaches suffer from
disadvantages,20 including unpredictable drug uptake rates, the limited diffusion and
lifetime of 1O2, and the requirement for moderate levels of O2 which may not always be
available in the tumor environment.
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In this chapter, we report a new light-targeted drug delivery system, which operates
independently of the creation of 1O2. The basis of the system is the attachment of a cell
impermeable small molecule to a drug via a linker that can be removed in presence of
light, allowing cellular entry (Figure 1). We call this new strategy photocaged
permeability (PCP).21

Figure: 2.1. Photocaged permeability strategy for drug delivery
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2. 2. Building blocks to design photocaged drug conjugate
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As mentioned before, we envisioned to synthesize a cell impermeable drug conjugate.
For this purpose, we followed a stepwise procedure to gather the components that would
be used to build a desirable drug conjugate.
Drug:
Doxorubicin, a clinically approved, cell-permeable, anticancer drug was chosen for this
study because of its intrinsic fluorescence (λ ex/em=470/590) 32.
Doxorubicin also can be easily modified and functionalized at the free amine group (Fig.
2.2 a), which renders the molecule non-cytotoxic33.
Photocleavable linker
As mentioned earlier in chapter 1, we were able to acquire the commercially available
ONB derivatized photocleavable linker (Fig 2.2 d) that has two functional groups and
could be modified to attach a drug and a hydrophilic moiety.
Hydrophilic Moiety
At the onset of this project, we sought a hydrophilic molecule that was reported to be cell
impermeable. Sulfonic acid groups are highly impermeable compared to other functional
groups

22

. Hence, we sought several molecules that had sulfonic acid functional group

and concluded our search after finding APTS (8-Aminopyrene-1,3,6-trisulfonic acid) and
EDANS ((5-((2-Aminoethyl)amino)naphthalene-1-sulfonic acid).
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APTS:
APTS (Fig 2.2 b) is green fluorescent dye often used to tag saccharides for separation and
detection by capillary electrophoresis27. This molecule has three sulfonic acid functional
groups in its structure. Hence, we first synthesized APTS 1 using a previously published
report28, and then envisioned to synthesize the drug conjugate using the following
synthetic schemes.
Synthesis of APTS-Photocage conjugates using peptide coupling chemistry
Our very first goal was to synthesize a conjugate of APTS-photocage using standard
coupling chemistry (Scheme: 1).
Route A:
For this purpose, we first synthesized a succinimidyl ester of photocage molecule
(activates the carbonyl bond), which was later made to react with APTS in presence of
triethylamine (TEA) in the dark. The progress of reaction was monitored on TLC, which
indicated that the reaction was not progressing to form expected product, but rather
remained unreacted.
Route B and Route C:
Later, we ventured into other commonly used and efficient coupling mechanisms to form
the conjugate. In Route B, we used DCC (N, N’-Dicyclohexylcarbodiimide) in the
presence of TEA and HBTU in presence of TEA (acts similar to DCC). Even at higher
temperatures, as indicated by TLC, these reactions did not proceed as expected. We
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reasoned that the sulfonic acid functional groups highly deactivated the pyrene ring; as a
result we were not able to proceed with coupling chemistry.

Scheme 2.1: Synthesis of APTS-Photocage conjugate using coupling chemistry
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Reductive Amination of APTS to attach linker:
We then turned our attention to derivatize APTS using a reductive amination reaction
which appeared to be facile based on a literature precedent28.

Also, we figured that click chemistry is a viable option to attach APTS to our photocaged
drug, as it is a high yielding and has previously been demonstrated30 to be a successful
reaction to couple two different entities. Hence, we decided to prepare a derivatized
APTS with an azide analog such that it could undergo click chemistry.
Synthesis of APTS-Azide linker
The synthesis as described in scheme 2.2 began with mono-tosylation of triethylene
glycol 2.1 in the presence of tosyl chloride and triethylamine to give 2.2. This compound
was treated with an excess of sodium azide to yield azido triethyleneglycol 2.3. Further,
this white colored solid underwent Swern Oxidation, in presence of DMSO, oxalyl
chloride and TEA, to give aldehyde 2.4. Finally, we stirred APTS 2.5 along with 2.4 in
presence of sodium borohydride in methanol and anticipated formation of the imine 2.6.
Unfortunately, this reaction did not proceed as analyzed by TLC and NMR.
Thus, after multiple reaction trials and different reaction conditions, we discontinued the
pursuit to synthesize a drug conjugate using APTS as hydrophilic moiety. We now sought
a different molecule with a sulfonic acid functional group and with a more reactive alkyl
amine.
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Scheme: 2.2 Synthesis of APTS –linker. Reagents and conditions
a) Tosyl chloride, Triethylamine (TEA), DMF at 0oC. b) Sodium azide at 50oC c) Oxalyl
chloride, DMSO, TEA -78 oC. d) Sodium cyanoborohydride in MeOH
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EDANS:
EDANS is also a sulfonated dye (Fig 2.2 c) often used in conjunction with DABCYL as a
FRET pair29. As seen in the figure, it has an ethylene diamine unit, which was easily
modifiable and could be used for the coupling reaction. Hence, we proceeded with this
molecule as the hydrophilic moiety.
Syntheses of EDANS-Azide conjugate:
At this point, we designed a scheme to synthesize an azide derivative of EDANS. We
first acquired 4-azido benzoic acid (4) and then converted it to succinimidyl ester
derivative (4) in presence of EDAC and NHS. Later, we attached EDANS to the activated
ester molecule, to give the azide derivative of EDANS (5). The derivative was easily
purified on flash column chromatography and was taken further towards click chemistry.

Scheme 2.3 Synthesis of EDANS-Azide conjugate
a) NHS, EDAC, DMF. (b) EDANS, Et3N
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Retrosynthetic analysis
With our azide-containing sulfonic acid in hand we planned to assemble the desired
photocaged Dox in the following manner.

We planned to attach the nitroveratryl

compound to Dox via a carbamate linkage formed from a p-nitrophenyl carbonate.
Secondly we planned to attach the sulfonated EDANS to the dox conjugate using click
chemistry.

Click
chemistry

Displacement of pnitrophenyl
carbonate
Doxorubicin

Photocage linker

Hydrophilic moiety

Fig. 2.2. Strategy for synthesis of photocaged dox and EDANS conjugate.
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Scheme 2.4: Synthesis of photocaged-cell impermeable drug conjugate. Reagents and conditions: (a) NHS, EDC-HCl; (b)
propargylamine, Et3N; (c) bis p-nitrophenylcarbonate, Et3N; (d) doxorubicin-HCl, Et3N; (g) CuSO4·5H2O, sodium ascorbate, tris(benzyltriazolylmethyl)amine, DMSO: water (1:1)
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2. 3. Synthesis of the photocaged-drug conjugate
The synthesis (Scheme 1) began with commercially available nitroveratryl carboxylic
acid (2.9). We first prepared the N-hydroxy succinimidyl ester 2.10 using N-hydroxy
succinimide in presence of EDAC, in DMF. This off white-colored solid was taken to the
next step without purification. This solid was solubilized in a solution of propargylamine
in DMF, in presence of triethylamine base (TEA). The reaction yielded pale, white
alkyne 2.11 in good yield after purification. The benzylic alcohol of 2.11 was reacted
with bis-p-nitrophenol to form the activated mixed carbonate 2.12 in moderate yield. The
nitrophenyl group of 2.12 was displaced with doxorubicin to give Dox alkyne 2.13.
Purity of the obtained solid was verified by HPLC (Fig. 2.4)
Finally we coupled 2.8 and 2.13 (Scheme 2.4) solublized in 1:1 DMSO and water, in
presence of CuSO4, sodium ascorbate and TBTA which gave 2.14, a red colored solution
that was purified on RP-HPLC (Fig. 2.5) to give 41% of product. HRMS of the final
compound is shown in Fig. 2.6.
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HPLC Purity analysis of Photocaged Doxorubicin:

% of B or
acetonitrile

Fig. 2.3: RP- HPLC analysis of (2.13) at using detection at 480 nm. The two
diastereomers have retention times of 35.8 and 36.9 min
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HPLC purity analysis of EDANS-DOX drug conjugate:

% of B or
acetonitrile

Fig. 2.4: RP- HPLC analysis of EDANS-Dox (2.14), using absorbance at 480 nm. The
two diastereomers have retention times of 31.25 and 32.28 min.
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Fig. 2.5: HRMS (ESI) C63H63N8O22S of cell impermeable photocaged drug conjugate
Calculated (M) - =1315.378; Observed=1315.343
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2. 4. Photolytic assay
The photolytic release of doxorubicin from the drug conjugate was analyzed using
HPLC. The drug conjugate was dissolved in PBS buffer and was exposed to UV light at
365 nm (9.0 mW/cm2). Aliquots of the reaction mixture were collected at various times
and were analyzed on RP-HPLC. During the course of the reaction, the peaks
corresponding to the Dox-EDANS conjugate disappeared with concomitant increase in
the intensity of a peak with the same retention time as Dox (Figure 2.7), confirming timedepended drug release in the presence of light.
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a)

e

Time
of UV
exposure

Retention time

Fig. 2.6: a) Release of free dox with upon irradiation over time under UV light. A
solution of compound 2.14 was irradiated. Samples were removed at various time points
(0.5, 1, 2, 4, 8, 15, 20, and 30 min) and were analyzed by RP-HPLC at λ = 480 nm. The
compound in the dark (t = 0) and free doxorubicin are included as standards. b) Graph
representing increase in intensity of integrated peak area of doxorubicin in the above time
dependent photolysis experiment.
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Cell line used in this project:
For the purpose of the in vitro studies using drug conjugate, we used JH-EsoAd1 cell
line, a Barrett's esophagus associated adenocarcinoma cell line. There are a couple of
reasons to choose this cell line. The most important reason is that the other esophageal
cancer cell lines such as OE33 and OE19 that are currently being used in research have
been shown to be from other tissue types. But this cell line has been established 25 to be a
bona fide version of the esophageal adenocarcinoma cell line after extensive testing.
Esophageal tissues have been previously shown to be accessible via endoscope in PDT,
and PDT is a currently FDA approved treatment for the pre-malignant condition of
Barrett’s esopagus31. Likewise, we ultimately aim to activate our photocaged drug
molecule, in malignant organs that are accessible via endoscope, such as esophagus.
Hence, we chose esophageal cell lines, for in vitro assays; to mimic the physiological
conditions.
2. 5. Flow cytometry and Confocal microscopy assays
We then investigated whether the attachment of EDANS to Dox via the veratryl linker
would enable drug delivery. JH-EsoAd1 cells25 were incubated with Dox-EDANS in the
dark or with illumination. Cell permeability was measured with flow cytometry; upon
illumination a significant enhancement of cellular Dox fluorescence was observed
(Figure 2.8 A–B). This enhancement was mirrored in confocal studies with the same cell
line (Figure 2.8 C)—only light-treated cells show significant Dox fluorescence in the
nucleus, where it is known to accumulate.26
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A)

B)

C)

Fig.2. 7: (A). The flow cytometry histogram displays the relative fluorescence intensity of untreated controls in the dark (blue) or
light (red) or JH-EsoAd1 cells treated with EDANS-Dox in the dark (orange) or light (green). (B) Quantification of Dox fluorescence
for the indicated treatment conditions. Data are representative of two independent experiments, N = 9. (C) Representative confocal
images of JHEsoAd1 cells treated with EDANS-Dox in the dark or light. The red channel shows Dox fluorescence, the gray channel is
a DIC image, and the overlay represents the cellular localization of Dox fluorescence.
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2. 6. Cell viability assay
With permeability enhancement established, we proceeded to investigate the extent to
which the release of Dox with light would lead to enhanced cellular toxicity. For this
purpose, we performed two sets of experiments. In both the experiments, we incubated
the cells with drug conjugate at increasing time intervals at 0, 5, 10, 20 and 40 minutes.
The first experiment was conducted in the dark whereas the second one under the
continuous irradiation of UV light. We found that, increased illumination lead to
decreased survival as measured by an MTT assay (Figure 2.9). Survival of cells treated
with EDANS-Dox in the dark was equivalent to controls with no drug added. Moreover,
treatment with light alone at the same dose was not cytotoxic (Figure 2.10).
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Fig. 2.8: Light-dependent cytotoxicity of Dox-EDANS. Cells were treated with 10 μM of
Dox-EDANS with (solid diamonds) or without (open squares) light for the specified
times. After 2 h, the cells were washed with fresh media and allowed to grow for 72 h.
The fraction of surviving cells was evaluated using the absorbance of the formazan
product of MTT reduction. *Error bars denote one standard deviation from the mean.
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Fig. 2. 9: Effect of light and EDANS on cell survival. JHEsoAd1 cells were treated with
EDANS in the dark (blue diamonds), EDANS + light (open squares) (9 mW/cm2) or light
alone (black diamonds) for the specified times. Cell survival was determined using the
MTT assay. Each data point was taken from a minimum of six replicate experiments.
Error bars are omitted for clarity.

69

IC50 value of the drug conjugate
Finally, we sought to compare the concentration dependence for our method vs. Dox
alone. We first measured the IC50 of Dox alone replicating the above mentioned MTT
assay with the JH-EsoAd1 cells and found it to be 1.0 ± 0.4 μM (Figure 2.11).

Fig.2.10: Concentration-dependent toxicity of compounds on JH-EsoAd1 cells. % cell
viability was plotted for JH-EsoAD1 cells at various concentrations of EDANS-Dox in
the dark (open squares) or with light (black diamonds, black line), and unconjugated Dox
in the dark (red circles, red line) or with light (blue diamonds, blue line). Experiments
were performed in at least six replicates. Error bars are omitted for clarity. The lines are
plots of the curve fits of the relevant data to the equation: Y = M1+ (M2-M1)/(1+X/M3).
The constant M3 describes the IC50 value.
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When the MTT assay was performed on cells incubated with the EDANS-Dox drug
conjugate it was not toxic to the cells in the dark at the highest value tested (16 μM).
However, illumination of EDANS-Dox (365 nm, 9.0 mW/cm2) leads to cytotoxicity with
an IC50 of 1.6 ± 1.0 μM (Figure 2.12), comparable to that of Dox alone. Based on our
FACS study (Figure 2.8), we deduce that this enhanced cytotoxicity is caused by efficient
light-stimulated release of free Dox from the impermeable EDANS.
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Fig: 2. 11: Concentration-dependent, light-stimulated cytotoxicity. Cells were treated
with EDANS-Dox at various concentrations in the dark (open squares) or with UV light
for 20 min (black diamonds). After 2 h, the cells were washed with fresh media and
allowed to grow for 72 h. The fraction of surviving cells relative to no drug controls was
evaluated using the absorbance of the formazan product of MTT reduction. Error bars
denote one standard deviation from the mean.
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2. 7. Discussion
The aim of this project was to develop a new and efficient strategy for drug release based
on photocaged permeability (PCP).
At the outset of this project, we envisioned to use APTS (8-aminopyrene-1, 3, 6trisulfonate) as the hydrophilic moiety that would have contributed to the impermeability
of the drug conjugate. But due to the sulfonic acid functional groups, the pyrene ring was
highly deactivated; as a result of which most of the reactions did not proceed efficiently.
Also, purification of the molecules on HPLC seemed a big challenge. As a result, we
used EDANS, a smaller, simpler to handle, cell impermeable molecule instead.
We chose doxorubicin as drug molecule, because it was previously described as cell
permeable and for the photosensitive linker we chose a nitroveratryl derivative, which
was modified to attach doxorubicin and EDANS.
Once we synthesized the drug conjugate using the scheme mentioned in Scheme 2.4, we
initially performed the photolysis assay to determine the efficiency of the drug conjugate
to photo release the drug molecule. Later, we performed MTT (cell viability) assays
using esophageal adenocarcinoma (JH-EsoAd1) cells to determine the efficiency of our
drug conjugate to induce cell death. As expected, our drug conjugate was able to induce
cell death, but only in the presence of light. Also, we did several control studies to
substantiate the fact that the cell death was actually due to drug release but not due to
light or other entities. Further, we performed FACS (Fluorescence Assisted Cell Sorting)
and confocal assays to show that in dark, the drug conjugate did not permeate cells. But
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upon irradiation with UV light, the drug was released from the conjugate, permeated the
cells and induced cell death.
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2. 8. Experimental section
1. General
All reagents were purchased from Sigma-Aldrich, Fisher Scientific or TCI America
unless otherwise specified and were used as received. Dimethyl formamide (DMF) used
as solvent for chemical synthesis was dried by vacuum distillation. All reactions were
carried out in oven dried glassware and under Ar or N2 atmosphere. The reactions were
carried out in foil-wrapped flasks, protected from light. Flash chromatography was
performed using Flash Silica Gel (32-63μ). 1H NMR/

13

C spectra were recorded on 400

MHz Bruker AVANCE and 300 MHz Varian instruments. HPLC purification was carried
out using a Shimadzu Prominence system using Vydac (218TP C18 5μ) column using
0.1% TFA in acetonitrile and water as eluents and was monitored at λmax = 480 nm. MS
data was collected using Micromass MALDI-R/TOF (positive modes) unless mentioned.
The UV lamp used in all studies consisted of a simple aquarium light fixture containing
two Philips PL-S 9w/2P BLB bulbs.
The Esophageal cancer cell line (JH-EsoAd1) was cultured at 37o C and in a humidified
atmosphere of 5% CO2 in RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS). For 96 well plate experiments, the JH-EsoAd1 cells were seeded at 4450
cells/well in 100 μL of media in 96 well plates; experiments were carried out one day
after seeding. MTT assays were analyzed using a Bio-Tex μQuant plate reader at 562 nm.
FACS was performed BD FACS Aria II using BD FACS Diva software at the VCU Flow
Cytometry Core Facility. A minimum of 20,000 cells within the gated region were
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analyzed. Confocal microscopy images were acquired at room temperature with a Leica
confocal laser scanning microscope.
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2.9. Chemical Synthesis
Synthesis of 2,5-dioxopyrrolidin-1-yl 4-(4-(1-hydroxyethyl)-2-methoxy-5nitrophenoxy)butanoate (2.10)

4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy) butanoic acid (2.9) (200 mg, 0.67
mmoles) was dissolved in 10 ml of DMF and stirred for 5 minutes at 0oC. To this
mixture, EDC. HCl (1.5 eq., 156 mg, 1.0 mmoles) was added followed by NHS (1.5 eq.,
115 mg, 1.0 mmoles). The reaction was stirred under N2 atmosphere in the dark at 0oC
for approximately 1 h and then at rt for 15 h. DMF was removed in vacuo. To this
mixture, 30 ml of EtOAc was added followed by extraction with water (3x 20 ml). The
organic layer was dried with MgSO4, filtered and the solvent was removed under reduced
pressure. The product obtained was single spot on TLC and was taken to the next step
without purification.
1

H NMR (CDCl3, 400 MHz):

δ =7.57 (s, 1H, Ar-H), 7.39 (s, 1H, Ar-H), 5.52-5.56 (m, 1H, CH3-CH),4.17 (t, 2H, -CH2,
J = 5.6 Hz), 3.98 (s, 3H, -OCH3), 2.85 (m, 6H), 2.29 (br.s, 1H, -CH), 2.2 (m, 3H), 1.52
(d, 3H, -CH3, J =4.4 Hz).
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Synthesis of 4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy)-N-(prop-2-yn-1-yl)
butanamide (2.11):

2.10(250 mg, 0.63 mmol) was dissolved in 5 ml of DMF and stirred for 5 minutes. To
thissolution, triethylamine (2 eq., 175 μL, 1.26 mmol) was added dropwise followed by
propargylamine (2 eq., 70 mg, 1.26 mmol). The reaction was stirred overnight at rt under
N2 gas, in dark. Then, DMF was removed under high vacuum. To the resulting pale
yellow oil was added EtOAc (25 ml), followed by washing with water (3 x 20 mL). The
organic layer was dried over MgSO4 and filtered; the solvent was removed and purified
using column chromatography (100% EtOAc) to yield pale white solid (153 mg, 72%).
1

H NMR (CDCl3, 400 MHz):δ =7.57 (s, 1H, Ar-H), 7.31 (s, 1H, Ar-H), 5.93 (br. s, 1H,

N-H), 5.55-5.58 (m, 1H, CH3-CH),4.12 (t, 2H, -CH2, J = 5.6 Hz), 4.06 (dd, 2H, -CH2, Jab
= 2.4 Hz, Jac = 5.2 Hz ), 3.9 (s, 3H, -OCH3), 2.45 (t, 2H, -CH2- , J = 6.8 Hz), 2.21 (br.s,
1H, -CH), 2.2 (m, 3H), 1.56 (d, 3H, -CH3, J =4.4 Hz).
13

C NMR (CDCl3, 75 MHz):

δ = 24.7, 24.9, 29.3, 32.7, 56.5, 65.7, 68.6, 71.7, 79.8, 108.9, 109.2, 137.9, 139.4, 146.8,
154.14, 172.5.
MS (MALDI-TOF+): C16H20N2O6Na; calculated. (M+Na)+ 359.12, found= 359.27
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Synthesis of 1-(5-methoxy-2-nitro-4-(4-oxo-4-(prop-2-yn-1ylamino)butoxy)phenyl)ethyl (4-nitrophenyl) carbonate (2.12):

To a stirred solution of 2.11 (100 mg, 0.30 mmol) in dry DMF (10 ml) was added
triethylamine (83μL, 2 eq., 0.59 mmol) followed by bis (4-nitrophenyl)carbonate (271
mg, 3 eq., 0.89 mmol). The solution was stirred overnight in the dark at rt after which it
was cooled and acidified with 20 mL of 1% HCl. The mixture was extracted with 30 mL
of EtOAc and the organic layer was washed with saturated NaHCO3 (3x20 mL) solution
and brine (1x 20 mL) and dried over MgSO4. The solution was filtered, concentrated and
purified by flash column chromatography (1:1 to 7:3 EtOAc: hexanes) to yield pale
yellow colored solid. (81 mg, 54 %).
1

H NMR (CDCl3, 400 MHz):δ = 8.26 (d, 2H, Ar-H, J = 9.2 Hz), 7.61 (s, 1H, Ar-H),

7.36(m, 2H, Ar-H), 7.12 (s, 1H, Ar-H), 6.53(q, 1H, CH3-CH, J = 6.4 Hz), 5.91 (br. s, 1H,
N-H), 4.14(t, 2H, -CH2, J = 6.0 Hz), 4.06 (dd, 2H, -CH2, J12 = 2.4 Hz, J13 = 5.2 Hz), 4.01
(s, 3H, -OCH3), 2.45 (t, 2H, -CH2, J = 7.2Hz), 2.21( m, 3H), 1.78 (d, 3H, -CH3, J = 8.0
Hz).
13

C NMR (CDCl3, 100 MHz):δ = 21.9, 24.6, 29.2, 32.5, 56.54, 68.49, 71.5, 73.7, 79.5,

108.0, 109.1, 115.7, 121.66, 131.4, 139.9, 145.4, 147.6, 151.4, 154.1, 155.3, 171.8.
MS (MALDI-TOF+): C23H23N3O10Na; calculated. (M+Na)+ =524.13, found =524.29
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Synthesis of photocaged doxorubicin (2.13):

To a stirred solution of 2.12 (80 mg, 0.16 mmol) in dry DMF (3 ml) was added
triethylamine (45 μL, 2 eq., 0.32 mmol) followed by Dox (44 mg, 0.5 eq., 0.08 mmol).
The solution was stirred at rt for 24 h under nitrogen, in the dark. Then, DMF was
removed under low vacuum. To this red colored solid, 30 ml of EtOAc was added and
washed with water (3 x 20 ml). The organic layer was dried over MgSO4, filtered and the
solvent was removed and purified using column chromatography (silica/EtOAc and then
1:10 MeOH: CHCl3) to yield 52% of a mixture of diastereomers. The resulting solution
was purified on RP-HPLC using isocratic elution of 20 % organic eluent (0.1 % TFA in
acetonitrile) for 5 minutes and then using gradient elution from 20% to 70% for 30
minutes. The two diastereomers eluted at 35.8 and 36.9 min (See figure 2.6). The NMR
analysis showed the presence of two products corresponding to the two diastereomers.
1

H NMR (DMSO-d6, 400 MHz): (2x means both diastereomeric products had

indistinguishable ppm values for those protons)
14.05 (s,1H), 14.0 (s,1H), 13.27 (s, 2x1 H), 7.92 (m, 2x2H), 7.66 (m, 1x2H), 7.54 (s, 1H),
7.49 (s,1H), 7.17 (s, 1H), 7.13 (s,1H), 6.05 (m, 2x1H), 5.41 (m, 2x1 H), 5.21-5.23 (m,
2x1H), 4.95 (m, 2x1 H), 4.78-4.84 (m,2H), 4,66 (m, 2x1), 4.55 ( m, 2x2H), 3.82-4.14 (m,
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2x11H), 3.64-3.73 (m, 4H), 3.51 (m,1x2 H), 3.05 (t, 1H, J = 2.4 Hz), 3.08 (t, 1H, J = 2.4
Hz), 2.97 (m, 4H), 2.90 (s, 1H), 2.74 (s, 1H) 2.18-2.28 (m, 6H), 1.83-1.85 (m, 4x2H),
1.48 (m, 3x2H), 1.10 (m, 3x2H).
13

C NMR (DMSO, 100 MHz):

21.92, 27.78, 46.91, 46.99, 56.15, 56.23, 56.26, 56.42, 60.18, 63.7, 66.73, 68.21, 69.74,
72.73, 74.89, 81.21, 100.2, 108.44, 108.66, 110.41, 110.56, 118.8, 118.83, 119.47,
119.73, 128.6, 133.54, 134.4, 135.2, 135.27, 135.98, 139.0, 139.22, 146.65, 146.69,
153.58, 154.37, 155.68,155.92, 160.64, 171.24, 171.3, 186.22, 213.81.
MS (MALDI-TOF): C44H47N3O18Na; calculated. (M+Na)+ 928.28, found 928.43.
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Synthesis of 2, 5-dioxopyrrolidin-1-yl 4-azidobenzoate (2.7):

4-azidobenzoic acid (2.6) (500 mg, 3.065 mmol) was dissolved in 10 ml of DMF cooled
to 0oC. To this mixture, EDC. HCl (1.2 eq., 570 mg, 3.678 mmol) was added followed by
NHS (1.2 eq., 424 mg, 3.678 mmol). The reaction was stirred in the dark under N2 at 0o C
for approximately 1 h and then at rt for 15 h. DMF was removed in vacuo. This
concentrated mixture was dissolved in 30 ml of EtOAc and then extracted with water (3x
20 ml). The organic layer was dried over MgSO4, filtered, evaporated and purified using
column chromatography (100% EtOAc) to yield 97% of pale yellow colored product.
1

H NMR (DMSO, 400 MHz):

δ = 8.11 (d, 2H, Ar-H, J = 8.8 Hz), 7.36 (d, 2H, Ar-H, J = 8.8 Hz), 2.90 (s, CH2, 4H).
13

C NMR (DMSO, 100 MHz):

δ = 25.48, 120.06, 120.46, 131.98, 146.80, 161.06, 170.32.
MS (MALDI-TOF): C11H8N4O4Na; calculated. (M+Na)+ 283.04, found: 283.28
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Synthesis of 5-((2-(4-azidobenzamido)ethyl)amino)naphthalene-1-sulfonic acid (2.8):

To a stirred solution of 2.7 (50 mg, 0.192 mmol, 1.1 eq.) in dry DMF (10 ml) was added
EtN(iPr)2 (46 μL, 1.5 eq., 0.262 mmol) followed by EDANS (47 mg, 1 eq., 0.174 mmol).
The turbid, brown solution was stirred at rt for 10 h under nitrogen. The solvent was then
removed under low vacuum. To the resulting brown, thick oil, 30 ml of CH2Cl2 was
added and washed with water (3x20 ml). The organic layer was dried over Na2SO4,
filtered and the solvent was removed in vacuo and purified using column chromatography
(silica/15:85 MeOH: CHCl3) to yield 46 mg (64%) of a brown solid.
1

H NMR (DMSO, 400 MHz):

δ = 8.72 (t, 1H, -CONH-, J = 6.0 Hz), 8.07 (d, 2H, Ar -H, J = 8.4 Hz), 7.88 (m, 3H, ArH), 7.27 (dd, 2H, -CH2, J12 = 7.2 Hz, J13 = 8.4 Hz), 7.21 (dd, 2H, -CH2, J12 = 8.0 Hz, J13 =
7.6 Hz), 7.14 (m, 2H, Ar-H), 6.58 (d, 1H, Ar-H, J = 7.2Hz), 3.54 (m, 2H, -CH2), 2.99 (m,
2H, -CH2-).
13

C NMR (DMSO, 100 MHz):

δ = 25.20, 45.6, 102.7, 115.6, 118.9, 122.3, 126.2, 129.1, 130.1, 130.9, 142.2, 143.71,
143.9, 165.8, 172.7.
MS (MALDI-TOF): C19H17N5O4SNa; calculated. (M+Na)+ 434.09, found: 434.69
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Synthesis of photocaged-cell impermeable dox. conjugate (2.14):

Compounds 2.8 (50 mg, 0.055 mmol, 1eq.) and 2.13 (21.7 mg, 0.05 mmol, 1eq.) were
stirred in 1:1 mixture of water and DMSO (4 mL each). 100 μL (1 mg, 0.005 mmol, 0.1
eq.) of freshly prepared aqueous solution of sodium ascorbate (10 mg/mL) was added to
the reaction, followed by 10 μL (0.125 mg, 0.01 eq., 0.0005 mmol) of freshly prepared
aqueous solution of copper (II) sulfate pentahydrate (12.5 mg/ mL) was added and finally
2.65 mg (0.1 eq., 0.005 mmol) of TBTA was added. The red colored heterogenous
mixture was stirred vigorously until the reaction was completed (~24h) as judged by TLC
(1: 4 CH3OH/CHCl3). The reaction mixture was concentrated in vacuo, filtered and the
resulting solution was purified on RP-HPLC using isocratic elution of 20 % organic
eluent (0.1 % TFA in acetonitrile) for 5 minutes and then increasing the acetonitrile
fraction in gradient fashion from 20 % to 70% over 30 minutes at 0.5 ml/min. The
fractions (~3 mL each) were collected into tubes containing 500 μL of ammonium
bicarbonate (2 mg/ mL) solution to quench the TFA. The two diastereomers eluted at
31.25 and 32.28 min.

The fractions containing the diastereomers were evaporated

leaving a red solid (30 mg, 41%). One of the diastereomers was isolated for proton NMR
analysis.
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1

H NMR (DMSO, 400 MHz):

δ =14.06 (s, 1H), 13.29 (s, 1H), 8.85 (t, 1H, J = 3.6 Hz), 8.72 (s, 1H), 8.44 (t, 1H, J = 5.2
Hz), 8.12 (m, 1H), 8.08 (d, 2H, J = 8.8 Hz), 8.02 (d, 2H, J = 8.8 Hz), 7.91- 7.94 (m, 2H),
7.66- 7.68 (m, 1H), 7.54 (s, 1H), 7.24 - 7.34 (m, 3H), 7.15 (s,1H), 7.0- 7.02 ( m, 1H),
6.64 ( d, 1H, J = 7.6 Hz), 6.05 (m, 1H), 5.41( m, 2H), 5.22 ( s, 1H), 4.95 (m, 1H), 4.54 (s,
2H), 4.40 (m, 2H), 4.06-4.11 (m, 3H), 4.00 (s, 3H), 3.92 (s, 3H), 3.61 – 3.63 (m, 3H),
2.98 (m, 2H), 2.67 (m, 1H), 2.54 (m, 1H), 2.32(m, 2H), 2.15 (m, 2H), 1.98 ( m, 2H),
1.84( m, 2H), 1.45 (d, 3H, J = 6.4 Hz),1.09 (m, 3H).
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2. 10. Summary
In summary, we have focused on applying PCP to the light-stimulated delivery of Dox
into esophageal adenocarcinoma cells. In principle, the PCP approach could be applied to
any small, cell permeable molecule that has a free amine, hydroxyl, or carboxylic acid
group for attachment of the veratryl-EDANS molecule.
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CHAPTER: 3.

DUAL SPECIFICITY:

A NEW APPROACH TO INCREASE THE SPECIFICITY OF DRUG
TARGETING.
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Abstract:
Light is used as a source to improve the specificity of certain ligand-drug conjugates.
Here, we describe the synthesis of two drug conjugates appended to two different tumor
receptor binding ligands. These molecules are similar to the previously existing liganddrug conjugates, but differ in the fact that once internalized into the tumor cells; they
remain inactive, unless irradiated with light.
3.1. Introduction
Selectivity of pharmacological action is of central importance in drug therapy. Hence, the
development of targeted drug action is particularly important in minimizing the adverse
side effects associated with current cancer chemotherapeutics. Several approaches that
specifically target tumors have been reported 1. These approaches act either by interfering
with the oncogenic pathways2 or by targeting an over-expressed receptor3. The latter
approach employs a ligand that binds specifically to an over-expressed receptor and is
appended to a cytotoxic drug. This approach has an advantage over others because of
improved specificity of the drug action; hence reduced side-effects.
Folic acid (vitamin B9)4 is required in metabolic reactions in cells and is essential for
synthesis of nucleotide bases; this ligand has a high affinity towards folate receptors
(FRs). FRs are expressed normally in healthy tissues, but are expressed at elevated levels
in tumor tissues. Hence for this reason, FR targeting is actively being pursued for
imaging and therapeutic purposes by conjugating FA with the imaging or drug molecules.
PSMA (Prostate Specific Membrane Antigen) is a plasma membrane glycoprotein5 that is
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overexpressed in prostate cancer. Several ligands that display high binding affinity
toward PSMA are currently being used toward targeting the prostate cancer6.
But ligand targeted therapies have some inherent problems such as endosomal
entrapment and non-selective drug release. Endosomal entrapment refers to retention of a
drug conjugate inside the endosomes7. As a result, rapid release of the drug from
endosomes is not always efficient8. The other problem that affects ligand targeted therapy
is that the mode of activation of these drug conjugates is dependent only on few
functional groups that mediate facile release of the drug9; which could also happen even
before the conjugate internalizes, leading to non-specific drug action. In wake of these
limitations, a modified ligand-drug conjugate is essential that can overcome most of the
above mentioned drawbacks.
Light is a non-invasive source of drug activation and has been found to be efficient in
activation of drug molecules intracellularly10, 11, 21. PDT is tumor treatment modality that
depends on light and photosensitizer to produce singlet oxygen, a cytotoxic agent. But
application of PDT in tumor treatment is limited by the fact that there is not always
enough oxygen present in the tumor environment12. To address these limitations, we
recently reported a novel and efficient drug release system using photocaged drug
molecule13. Though this system works efficiently, a better system is needed to improve
the specificity of drug action.
In this chapter, we report the concept of Dual Specificity. In this approach, we envision
that by coupling a tumor-receptor targeting ligand (folic acid or PSMA binding ligands)
with photocaged drug molecule; the ligand-drug conjugate could selectively target the

93

tumor receptor, internalize and concentrate in tumor cells. And when irradiated with
light, the drug molecule is decaged; eventually causing cell death.
The advantages of this approach over the traditional targeted therapy would be that even
after internalization, the drug conjugate would remain latent; even if it leaks out of
endosomes. But once activated using light directed only to the tumor site, the drug is
cleaved from the conjugate and induces cell death.

Fig. 3.1: Strategy for dually specific drug delivery system
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3.2. Building blocks to design targeted photocaged drug conjugate

Receptor binding
ligand

Drug
Spacer

Receptor binding
ligand

Desirable characteristic of
ligands




Spacer

Desirable characteristic
of spacer


Tight binding with
tumor specific
receptor
Should have
functional group
that doesn’t
influence binding



Long enough to
give space for
ligand to bind
to receptor
Water soluble

Drug

Photocleavable Linker

Nitroveratryl linker
Doxorubicin
1) Light sensitive
2) Should have
functional
groups to hold
drug and
impermeable
moiety




Cell
permeable
Functional
group for
attachment

95

3.3 Design of targeted photocaged drug conjugate
In this section, we will be following the same steps that were previously described in
chapter 2, to design photocaged drug conjugated to tumor receptor binding ligands. In
that same chapter, we have rationalized the usage of drug and photocleavable linker
components. Hence in this section, we will focus only on the design of ligand and spacer.
Ligands:
Previously in our design of the drug conjugate, we attached a hydrophilic moiety to a
photocaged drug conjugate via ‘click’ chemistry. Without any major changes to the
existing design; we envisioned to replace the hydrophilic moiety with the tumor receptorspecific ligands.
At the onset of this project, we sought ligands that bound tightly to the tumor specificreceptor. Immediately, we found several vitamins, growth factors and some inhibitors
that exhibited high affinity towards their respective receptor and also were becoming
increasingly popular for the purposes of imaging and targeting drug molecules to the
tumor tissues. Hence, we concluded our search after finding Folic acid and 2-[3-(1, 3dicarboxypropyl)ureido]pentanedioic acid (DUPA) ligands. The folate receptor and
PSMA mechanism of drug internalization has already been described in chapter 1. Hence,
we will be focusing only on the design of the drug conjugate.
Folic Acid:
Folate receptors (FRs)4 are overexpressed in many different cancers such as ovarian,
lung, kidney, breast and brain. Folic acid-FA (vitamin B9) is a small molecule that has
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very high affinity towards FRs and binds tightly with them. For these reasons, FA
conjugated drug and imaging molecules are being used extensively in current research
and clinical studies.
Folic acid has two components, pteroic and glutamic acids (Fig. 3.2 a) that are conjugated
via a peptide bond. The α-COOH on glutamic acid is believed to play a key role in the
internalization of the folic acid-drug conjugate and γ-COOH was reported to be nonessential for FR binding. Hence, the γ-COOH was modified to attach a variety of
molecules. But there seems to be some controversy surrounding the previous statement20.
Recently, Baker, Jr. and group reported22 that conjugation on either α-COOH or γ-COOH
did not virtually affect the binding capability. But in any respect, both carboxylates play
some role in binding affinity toward FRs.
PSMA Binding Ligands
PSMA is the most commonly studied receptor associated with prostate cancer. These
receptors are overexpressed in prostate cancer. Recently, several groups initiated the
approach of using the low molecular weight ligands that selectively bind to PSMA to
study the progression of diseases. These ligands have been found to have sub-nanomolar
binding affinities towards PSMA6. Indeed, many of them have been radio-labeled, for
imaging studies and in some cases these ligands were conjugated to the drug molecules
for therapeutic purposes19.
The most commonly used PSMA binding ligands are urea derivatives (Fig. 3.2 b). Out of
many ligands analyzed; using in silico docking studies5, the DUPA ligand was found to
have multiple interactions with amino acids in the PSMA and hence displayed very high
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affinity. Interestingly, DUPA has three carboxylic units (α, γ, γ’), of which γ’ is found to
be non-essential for the binding purposes, similar to γ-COOH of folic acid. Hence the γ’COOH could be used to conjugate any imaging or therapeutic agents.

Site of drug
attachment

Site of drug
attachment

Fig. 3.2: a) Folic acid and b) PSMA binding urea based ligand
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Spacer:
Spacers are one of the important components that are incorporated into designs of any
receptor targeted drug conjugate to promote effective ligand-conjugate binding to the
receptor and also increase its solubility in physiological buffers. In general, spacers are
equipped with appropriate functional groups that can react with both the ligand and the
drug conjugates, so as to append one to another. The length of the spacer is critical for the
purpose of imaging and drug delivery, because if the length is too short, it may possibly
reduce the binding affinity and efficiency. But if the spacer is too long, it can potentially
loop back and then hinder the ligand-receptor interaction.
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Retrosynthetic analysis
After completing the synthesis of the ligand-spacer azide conjugates and photocaged dox
conjugate (Scheme 2.4), we planned to assemble the desired photocaged drug-ligand
conjugates using click chemistry as shown below.
.

Peptide coupling
reaction
Click
chemistry

Fig. 3.3: Strategy for synthesis of photocaged drug-ligand conjugate
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3.4 Design of ligand-spacer azide derivative for ‘click’ chemistry:
Since we had already established the protocol for synthesis of alkyne derivatized
photocaged doxorubicin (2.13), we envisioned to synthesize an azide derivatized ligand
spacer, such that we can couple both the entities via click chemistry.
Synthesis of Azide Derivatized Spacer
At this point, we first acquired an ethylene oxide spacer containing free amines (-NH2) at
each of its ends (3.1). Primarily, our main goals were to couple an azide moiety to one of
these amine units and use the other amine to couple to the ligand, via standard peptide
coupling chemistry.
In our attempt to synthesize the azide derivatized spacer (Scheme 3.1), we attached 4Azidobenzoic succinimidyl ester (2.7) to 1,8-Diamino-3,6-dioxaoctane (3.1) in the
presence of triethylamine and DMF. The azido-spacer product (3.2) was furnished in
good yield.

Scheme: 3.1 Synthesis of ligand-spacer azide derivative.
Reagents and conditions: a) Triethylamine (Et3N), DMF at 0oC to rt over 2 h
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Synthesis of Ligand-Spacer Azide Derivative
The synthesis of ligand-spacer conjugate is same for both ligands. But we will be
discussing the synthesis of each ligand-drug conjugate individually.
i)

Folic Acid-Spacer Conjugate

The synthesis of Folic acid-spacer conjugate (Scheme 3.2) started with solubilizing folic
acid (3.3) in DMF to form thick a viscous solution. To this solution, we added DCC and
N-hydroxysuccinimide to form the folate succinimidyl ester (3.4) which, after removal of
excess unreacted starting materials using acetone/ether precipitation, was taken to the
next step without further purification. This solid was stirred with azido derivatized spacer
(3.2), in DMF in the presence of triethylamine to give compound (3.5) in moderate yield.
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Scheme: 3.2: Synthesis of folic acid-spacer azide derivative.
Reagents and conditions: a) DCC, DMF b) 3.2, Et3N,
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i)

PSMA Binding Ligand-Spacer Conjugate

For the synthesis of the PSMA ligand, we first acquired L-glutamate di-tert-butyl ester
hydrochloride (3.6) and L-Glu(OBn)-OtBu (3.7), and coupled them via their amines
using triphosgene in basic conditions to form urea derivative 3.8. Later the benzyl group
on the core ligand was deprotected using Pd/C to give carboxylic acid 3.9. After
purification, this solid was treated with N-hydroxysuccinimide in presence of EDAC in
DMF to yield 3.10, which was taken to the next step without purification. To the solution
of 3.10 in DMF, we added the spacer (3.4) in the presence of triethylamine to form 3.11.
The Boc protecting groups were cleaved with 20% TFA in DCM to form an azidederivatized DUPA (3.12), in moderate yield.
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Scheme: 3.3: Synthesis of DUPA-spacer azide derivative. Reagents and conditions: a)
Triphosgene, Et3N, CH2Cl2b) H2, Pd/C, MeOH c) NHS, EDAC, DMF d) Et3N, DMF e)
20% TFA in CH2Cl2

105

Scheme 3. 4: Synthetic scheme for synthesis of photocaged drug-ligand conjugate
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3.5. Synthesis of photocaged drug-ligand conjugates
For the synthesis of folate and DUPA drug conjugates, we used both azide derivatized
ligands 3.5 and 3.12; coupled them with Dox alkyne 2.13 in two different reaction
vessels using click chemistry. The contents were solubilized in 1:1 DMSO and water in
presence of CuSO4, sodium ascorbate and TBTA which eventually yielded 3.13 as folate
drug conjugate in a low yielding reaction and 3.14 as DUPA drug conjugate. HRMS of
the red colored solid 3.13 is shown in Fig. 3.4
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Fig. 3.5: RP- HPLC analysis of 3.13, using absorbance at 480 nm. The two diastereomers
have retention times of 19.5 and 20.8 min.
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3.6. Representative photolytic assay to describe drug release from photocaged drug ligand conjugate
The photolytic release of doxorubicin from the photocaged drug-folic acid conjugate
(3.13) was analyzed using HPLC. The drug conjugate was dissolved in PBS buffer and
was exposed to UV light at 365 nm (9.0 mW/cm2). Aliquots of the reaction mixture were
collected at various times and were analyzed on RP-HPLC. During the course of the
reaction, the peaks corresponding to the 3.13 disappeared with concomitant increase in
the intensity of a peak with the same retention time as Dox (Fig.3.6), confirming timedepended drug release in the presence of light.
When the percentage release of doxorubicin relative to the drug conjugate was plotted on
the graph, it was found that the majority of doxorubicin was released within first 4
minutes of the irradiating the UV light and at the later time points, the drug release
plateaued. This data suggests that the doxorubicin release from the drug conjugate is
rapid.
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Fig. 3.6: Time dependent release of doxorubicin from the folic acid-photocaged drug
conjugate under UV light.
A solution of compound 3.13 was irradiated with UV light and samples were removed at
various time points (0.5, 1, 2, 4 and 8 min) and were analyzed by RP-HPLC at λ = 480 nm.
The compound in the dark (t = 0) and free doxorubicin are included as standards.
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Fig. 3.7: Graph representing increase in the % doxorubicin released from drug conjugate
over period of 8 minutes.
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3.7. Discussion and Conclusion
The aim of this project is to develop drug conjugates that have improved target specificity
due to the incorporation of light sensitive linker connecting tumor specific ligands to drug
molecule and test it on the tumor cells.
Here, we synthesized two different drug conjugates that are expected to bind only to
tumor cells. Specifically, we incorporated tumor receptor binding ligand (Folic acid and
DUPA) in our drug conjugate design and attached it to the photocaged doxorubicin
conjugate via click chemistry.

We later tested the efficiency of one of the drug

conjugates (Folic acid-drug conjugate) to release the drug molecule under UV irradiation.
We found that drug release from the conjugate is extremely fast and quantitative.
Future Directions:
In this project, our aim was to improve the selectivity of drug action by incorporating a
tumor specific receptor binding ligand in our photocaged drug conjugate design. And for
this purpose, we acquired two cell lines for each ligand-drug conjugate; one of the two
overexpresses the receptor protein and the other does not express the receptor at all.
Below, we throw some light on the cell lines that will be employed in future studies.
Cell lines
Folic acid:
We acquired two different cell lines, RT16 and R2 to demonstrate efficiency of the
photocaged drug conjugate. These two cell lines are isogenic cell line models which were
specifically developed to study certain antifolates14.
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RT16 is a CHO cell line that overexpresses FR-α, which has been developed by
transfections of cDNA of the folate receptor protein. Whereas R2 cell lines are used as
FR-null, which means the gene that expresses FRs in CHO cells has been knocked out.
PSMA
LnCaP cells are derived from metastatic lesion of prostatic adenocarcinoma of a human
patient15 that overexpress PSMA. These cell lines grow slower than other prostatic cancer
cell lines, a fact attributed to the overexpression of PSMA on their plasma membrane16.
DU145 cells17 are human prostate cancer cell lines which have been traditionally used for
prostate cancer research. These cell lines do not express PSMA at all and hence have
been used as negative control for PSMA dependent studies.
Cell Studies:
To reiterate the selectivity of the ligand towards their respective receptors, we will
initially perform confocal microscopy18 based assays using the above cell lines. Later, we
will be quantifying the amount of fluorescence in these cells using flow cytometry24. At
the end, we will be analyzing the viability of cells in presence of respective drug
conjugate using MTT assay25.
Conclusion:
Once the future goals of the described approach is completed, we will have two light
sensitive targeted drug delivery systems that can serve as better drug delivery vehicles for
tumor targeting and reducing side effects caused due to non-specific delivery.
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3.8. Experimental section
General
All reagents were purchased from Sigma-Aldrich, Fisher Scientific or TCI America
unless otherwise specified and were used as received. All reactions were carried out in
oven dried glassware and under Ar, H2 or N2 atmosphere. The reactions were carried out
in foil-wrapped flasks, protected from light. Flash chromatography was performed using
Flash Silica Gel (32-63μ). 1H NMR/

13

C spectra were recorded on 400 MHz Bruker

AVANCE and 300 MHz Varian instruments. HPLC purification was carried out using a
Shimadzu Prominence system using Vydac (218TP C18 5μ) column using 0.1% TFA in
acetonitrile and water as eluents and was monitored at λmax = 480 nm. M/S data was
collected using Micromass MALDI-R/TOF (positive modes) unless mentioned. The UV
lamp used in all studies consisted of a simple aquarium light fixture containing two
Philips PL-S 9w/2P BLB bulbs.
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3.9. Chemical synthesis of photocaged drug-folate conjugate
Synthesis of Photocaged doxorubicin has already been described in the experimental
section of Chapter 2.
Synthesis of N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-4-azidobenzamide (3. 2)

A solution of the NHS activated 4-azido benzoic acid (1) ( 260 mg, 1.0 mmol, 1eq.) in 7
mL of DMF was added dropwise over 30 mins into an ice-cooled solution of 2, 2’ethylenedioxy bis-(ethylamine) (1a) (600 mg, 4.0 mmol, 4 eq.) in 3 mL of DMF. The
reaction mixture was stirred for an hour at 0oC and then for about 5 h at room
temperature in dark condition. The solvent was removed in vacuo and the resulting
mixture was purified using flash column (4:2:0.1 DCM: EtOH: NH4OH) to give 79% of
the oily product (231 mg).
1

H NMR (CDCl3, 400 MHz):δ = 7.83 (m, 2H, Ar-H), 7.11 (br. s, 1H, CONH), 7.05 (m,

2H, Ar-H), 3.65 (m, 8H, -CH2-), 3.51 (t, 2H, J= 5Hz, -CH2-), 2.85 (t, 2H, J= 5Hz, -CH2), 1.90 (br. s, 2H, -NH2).
13

C NMR (CDCl3, 100 MHz): δ = 166.58, 143.12, 131.15, 128.95, 118.85, 73.18, 70.27,

70.11, 69.84, 41.62, 39.82.
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Synthesis of folate-linker (3.5):

Folic acid (1 g, 2.26 mmol) was dissolved in 20 mL of dry dimethylformamide (DMF) to
which 1.5 eq. of DCC (700 mg, 3.4 mmol) and 1.5 eq. of NHS (0.39 mg, 3.4 mmol) were
added. This formed a very viscous orange colored reaction mixture, which was stirred for
16 h at room temperature in the dark. The byproduct, dicyclohexylurea, was filtered off,
and 100 mL of 30% acetone in diethyl ether was added with stirring, which formed
orange precipitate. This precipitate was washed again with acetone: ether mixture for
several times. This mixture was then mixed with ether in a falcon tube; which was
vortexed vigorously and centrifuged at 2000 rpm. The ether supernatant was discarded
and the light orange-colored Folate-NHS ester was dried and taken to next step.
Folate-NHS ester (156 mg, 0.29 mmol) was dissolved in 20 ml of DMF while stirring. To
this solution, 2 eq. of 3.2 was added (170 mg, 0.58 mmol) along with 2 eq. of TEA (50
µL, 0.58 mmol). The mixture was stirred at room temperature in the dark for 16 h. After
DMF and TEA was evaporated, the resulting compound was washed with 30% acetone in
ether as mentioned above. The resulting solution was lyophilized to yield orange solid
that needed no further purification.

117
1

H NMR (CDCl3, 400 MHz):

8.64 (1H, m, Fol-H) , 8.55 (1H, m, 2x CONH), 7.83-7.92 (3H, m, spacer Ar-H and
CONH ), 7.56-7.63 (2H, m,Fol Ar-H ), 7.18-7.22 (3H, m, spacer Ar-H and -CONH),
6.89(1H, m, Fol-NH), 6.65 (2H, m, Fol Ar-H), 4.48 (2H, m, Ar-CH2), 4.24 (1H, m,-CH-)
3.40-3.57 (10 H, m, -CH2 -CH2 -O-), 3.17 (2H, m, -CH2 -CH2 -O-),), 2.16-2.25 (2H, m,
Glu-H), 1.91-1.93 (2H, m, Glu-H)

13

C NMR (CDCl3, 100 MHz):

174.29, 174.09, 171.98, 166.12, 166.10, 165.48, 165.44, 162.37, 161.20, 154.02, 150.69,
148.50, 148.45, 142.25, 142.19, 130.92, 130.88, 129.06, 128.79, 127.86, 121.54, 121.46,
118.84, 118.81, 118.77, 112.56, 111.24, 111.16, 69.63, 69.49, 69.40, 68.81, 66.65, 35.77
30.77
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Syntheses of fol dox conjugate (3.13):

Compounds 3.5 (32 mg, 0.044 mmol, 2 eq.) and 2.13 (21 mg, 0.022 mmol, 1eq.) were
stirred in 1:1 mixture of water and DMSO (2 mL each). 100 μL (1 mg, 0.005 mmol, 0.1
eq.) of freshly prepared aqueous solution of sodium ascorbate (10 mg/mL) was added to
the reaction, followed by 10 μL (0.125 mg, 0.01 eq., 0.0005 mmol) of freshly prepared
aqueous solution of copper (II) sulfate pentahydrate (12.5 mg/ mL) was added and finally
2.65 mg (0.1 eq., 0.005 mmol) of TBTA was added. The red colored heterogenous
mixture was stirred vigorously until the reaction was completed (~24h) as judged by TLC
(1: 4 CH3OH/CHCl3). The reaction mixture was concentrated in vacuo, filtered and the
resulting solution was purified on RP-HPLC using isocratic elution of 20 % organic
eluent (0.1 % TFA in acetonitrile) for 5 minutes and then increasing the acetonitrile
fraction in gradient fashion from 20 % to 100% over 30 minutes at 10 ml/min. The
fractions (~10 mL each) were collected into tubes containing 1000 μL of ammonium
bicarbonate (6 mg/ mL) solution to quench the TFA. The two diastereomers eluted at
19.5 and 20.8 min.
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3.10. Chemical Synthesis of DUPA-Photocaged drug conjugate:
Synthesis of (R)-5-benzyl 1-tert-butyl 2-(3-((S)-1,5-di-tert-butoxy-1,5-dioxopentan-2yl)ureido)pentanedioate (3.8).

Synthesis of 3.8 was performed according to a reported procedure5. To a solution of Lglutamate di-tert-butyl ester hydrochloride (333 mg, 1.12 mmol. 3 eq.) and triphosgene
(111 mg, 0.373 mmol. 1 eq.) in 10 mL DCM at −78 °C, triethylamine (322 µL, 2.31
mmol., 7 eq.) was added. After stirring for 2 h at −78 °C under argon, a solution of LGlu(OBn)-OtBu (330 mg, 1.19 mmol. 3.2 eq.) and TEA (210 µL, 1.5 mmol. 4 eq.) in 5
mL DCM was added. The reaction mixture was allowed to come to room temperature (rt)
over a period of 1 h and stirred at rt overnight. The reaction was quenched with 1 M HCl,
and the organic layer was washed with brine and dried over Na2SO4. The crude product
was purified using flash chromatography (hexane:EtOAc = 1:1) to yield a colorless oil.
1

H NMR (CDCl3, 400 MHz): δ= 7.314(5H, m, Ar-H), 5.007-5.143 (4H, m, urea-H and

Ar-CH2-), 4.302-4.404 (2H, m, -CH-), 2.263-2.488 (4H, m, -CH2-), 2.023-2.207 (2H, m, CH2-), 1.806-1.974(2H, m, -CH2-), 1.428-1.461 (27H, m, Boc-)
13

C NMR (CDCl3, 100 MHz):

173.1, 172.55, 172.38, 172.21, 157.33, 136.07, 128.64, 128.34, 128.29, 82.02, 81.95,
80.5, 66.48, 53.13, 53.07, 31.74, 30.54, 28.67, 28.59, 28.22, 28.13.
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Synthesis of (R)-5-(tert-butoxy)-4-(3-((R)-1, 5-di-tert-butoxy-1, 5-dioxopentan-2yl)ureido)-5-oxopentanoic acid (3.9).

To a solution of 9 (250 mg, 432 mmol) in MeOH, 5% Pd/C was added. The reaction
mixture was hydrogenated at 1 atm for 24 h at rt. Pd/C was filtered through a Celite pad
and washed with DCM. The crude product was purified using flash chromatography
(hexane:EtOAc = 40:60) to yield colorless oil (175 mg, 83%).
1

H NMR (CDCl3, 400 MHz):

5.40 (2H, m, Urea-H), 4.32-4.40 (2H, m, α-H), 2.29-2.41 (4H, m, Glu-H), 1.87-2.11 (4H,
m, Glu-H), 1.43-1.46 (27H, m, Boc)
13

C NMR (CDCl3, 100 MHz):

152.61, 152.20, 150.44, 150.37, 143.29, 114.30, 91.60, 87.31, 85.06, 83.68, 81.38, 63.50,
27.80, 27.25, 25.88, 25.37, 18.34
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Syntheses of Boc-protected DUPA-spacer conjugate (3.11):

150 mg (0.31 mmol, 1 eq.) of 3.9 was solublized in 10 ml DMF and stirred. To this
solution, 71 mg (0.614 mmol, 2 eq.) of NHS and 95 mg (0.614, 2eq.) of EDAC were
added and stirred overnight, in an aluminium foil covered flask. Later, the DMF solvent
was evaporated in vacuo and the crude reaction mixture was extracted with DCM and
water followed by brine solution. The impure white colored solid (3.10) was taken to next
step without further purification.
In the next step, the crude DUPA-NHS solid (~100 mg) was stirred in 10 mL DMF. To
this solid about 150 mg (0.512 mmol, ~3 eq.) of 3.2 was added to the mixture along with
triethylamine (71 μL, 0.512 mmol, 3 eq.) and stirred for about 16 h. The DMF was
evaporated and the crude mixture was extracted with DCM and 1 M HCl solution.. Later,
DCM was evaporated and the resulting brown colored oil was purified using a flash
column (10% MeOH in DCM) to yield 169 mg (63% with spacer contamination) of
brown colored oil.
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1

H NMR (CDCl3, 400 MHz):

7.88 (2H, d, J=8.4 Hz), 7.83 (2H, d, J=8.4 Hz), 7.38 (1H, m), 7.04-7.08(4H, m), 6.95 (1H,
m), 6.85 (1H, m), 5.80 (1H, d, J=8.4 Hz), 4.49 (1H, m), 4.13-4.18 (m, 2H), 3.41-3.6 (m,
24 H), 3.16-3.2 (m,1H), 2.25-2.29 (m, 5H), 1.41-1.46 (m, 37H)
Note: NMR indicates presence of extra linker despite extra careful purification.
13

C NMR (DMSO, 75 MHz):

167.09, 166.95, 165.87, 161.46, 161.34, 152.50, 138.06, 137.89, 125.77, 125.73, 123.79,
123.61, 113.69, 113.62, 76.74, 76.72, 75.38, 64.97, 64.75, 64.59, 64.07, 48.15, 47.74,
34.55, 34.03, 33.56, 27.62, 26.55, 24.40, 23.83, 22.82, 22.75, 22.71, 22.41
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Removal of Boc protection on DUPA-spacer conjugate (3.12):

.
To a solution of 3.11 (169 mg, 0.22 mmol) in 8 mL of DCM, 2 mL of TFA was added
and stirred for about 8 h at rt. Later, DCM and TFA were evaporated in vacuo. To the
pale colored oily solid, about 25 mL of cold ether was added. The suspension was
vortexed for about 5 minutes and then centrifuged in a 50 mL of falcon tube. This
procedure was repeated a second time yielding a brown colored oil 45% yield (50 mg).
1

H NMR (CDCl3, 400 MHz):

12.46 ( 3H, br.s, 3xCOOH), 8.50 ( 1H, m, CONH), 7.90 (2H, m, Ar-H), 7.19 (2H, m, ArH), 6.34 (1H, t, CONH, J= 8.8 Hz), 4.07-4.11 (2H, m, Urea-NH), 3.92 (2H, m, -CH-),
3.53 (8H, m, -CH2 -CH2 -O-), 3.41 (4H,m, -CH2 -CH2 -O-), 2.14-2.26 (4H, m, Glu-H),
1.73-1.92 (4H, m, Glu-H)
13

C NMR (DMSO, 75 MHz):

175.31, 175.27, 174.69, 158.02, 152.24, 129.35, 128.66, 113.18, 70.19, 69.72, 53.01,
52.68, 52.62, 52.03, 46.26, 32.29, 30.81, 29.13
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Syntheses of DUPA dox conjugate (3.14):

Compounds 2.13 (20 mg, 0.022 mmol, 1eq.) and 3.12 (27 mg, 0.044 mmol, 2eq.) were
stirred in 1:1 mixture of water and DMSO (2 mL each). 40 μL (0.4 mg, 0.002 mmol, 0.1
eq.) of a freshly prepared aqueous solution of sodium ascorbate (10 mg/mL) was added to
the reaction, followed by 12.5 μL (0.125 mg, 0.03 eq., 0.0006 mmol) of freshly prepared
aqueous solution of copper (II) sulfate pentahydrate (12.5 mg/ mL), and finally 1.1 mg
(0.1 eq., 0.002 mmol) of TBTA (Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) was
added. The red colored heterogenous mixture was stirred vigorously until the reaction
was completed (~24h) as judged by TLC (1: 4 CH3OH/CHCl3). The reaction mixture was
concentrated in vacuo, filtered and the resulting solution was purified on RP-HPLC using
isocratic elution of 20 % organic eluent (0.1 % TFA in acetonitrile) for 5 minutes and
then increasing the acetonitrile fraction in gradient fashion from 20 % to 100% over 30
minutes at 10 ml/min. The fractions (~10 mL each) were collected into tubes containing
1000 μL of ammonium bicarbonate (6 mg/ mL) solution to quench the TFA.
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CHAPTER: 4.

UPCONVERSION NANOPARTICLES MEDIATED DRUG DELIVERY
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Abstract:
Controlled release of the drug molecule from the photocaged drug conjugate suffers from
an intrinsic weakness of dependence on UV light. To address this limitation, we report
the synthesis of a photocaged drug conjugate that will be attached to Upconversion
Nanoparticles (UCNPs).
4.1. Introduction:
Current chemotherapy suffers from off-target action of the drug molecules and as a result
there are unwanted side-effects. To address this limitation, we reported two different
mechanisms of drug delivery, in Chapters 2 and 3, which are dependent on light.
Specifically, we demonstrated controlled release of the drug using a photocaged drug
conjugate as our first model and later described the design and synthesis of ligandphotocaged drug conjugate for site specific drug delivery. However, these drug delivery
systems suffer from a common intrinsic weakness of being activated only in the presence
of UV light.
The penetrability of UV radiation1, 2 into human skin is limited due to the fact that there is
absorption and scattering of the incident light due to cells and its organelles, blood
vessels etc. Also, UV light is reported to be cytotoxic3 as a result of high energy radiation
that can cause DNA damage4. As a result, photocaged drug conjugates that are UV
dependent for the purpose of drug delivery; face challenges when applied in vivo. Hence,
it is crucial to address the issue of drug release inside deep tissues, where external UV
light cannot penetrate.
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Upconversion Nanoparticles (UCNPs) refer to the lanthanide doped nanocrystals that
emit high energy rays when irradiated with NIR (Near Infrared) radiation (Fig. 4.1).
Specifically, the UCNPs are made of host lattices5 such as NaYF4, Y2O3 etc. embedded
with trivalent dopants such as Yb3+, Er3+ and Tm3+. Because of its upconversion
capability, these nanoparticles are currently being applied for the purposes of therapy6
and imaging7.
UCNPs are usually prepared in presence of certain capping ligands that control particle
growth and stabilize the particles against aggregation. These ligands contain functional
groups that are helpful for later functionalization of UCNPs with imaging or drug
molecules8, 9. Recently, Capobianco and group10 reported the usage of LiYF4:Tm3+,
Yb3+UCNPs, to demonstrate their ability to photoswitch. Specifically, these UCNPs were
attached to a bis-spiropyran moiety via dicarboxylate functional groups. When irradiated
with NIR, the non-fluorescent bis-spiropyrans underwent photoswitching to form
fluorescent merocyanine units.
We envision connecting photocaged doxorubicin onto the surface of the above mentioned
UCNPs via dicarboxylate units. Particularly, we will be designing and synthesizing the
photocaged doxorubicin-carboxylate ligand and using it toward functionalizing the
UCNPs. Later, we will be able to use the UCNP-drug conjugate for the purpose of drug
delivery under the irradiation of NIR.

131

UV (Ultraviolet)
NIR (Near Infrared)
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Fig. 4.1: Schematic description of UCNP mediated upconversion of NIR to UV
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4. 2. Building blocks to design photocaged drug-carboxylate ligand conjugate

Carboxylate ligand

Linker

Drug

Drug

Linker
Carboxylate ligand

Desirable characteristics of
the linker


Dicarboxylates for
the purpose of
functionalization




Light sensitive
Should have
functional groups
to hold drug and
dicarboxylate
ligand

Desirable characteristics of
the drug




Cell permeable
Functional group
for attachment
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Fig. 4.2 Graphical description of UCNP mediated drug release
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Since we already described the design of photocaged drug molecule (chapter 2), we will
just focus on the design of the dicarboxylate ligand in this section.
Dicarboxylate Ligand:
At the outset of this project, we envisioned to synthesize an azide derivatized
dicarboxylate unit, since we already have synthesized the photocaged doxorubicin (2.13),
which has an alkyne functionality; which will be later coupled via click chemistry.
We decided to use the same azide derivative of the benzoic succinimidyl ester (2.7) that
was previously used to derivatize various ligands (chapter 2 and 3).
Finally, we sought dicarboxylic units with an amine functionality that could be used in
coupling reaction with 2.7. We decided to use Boc-protected glutamic acid (3.6) for this
purpose (Fig. 4.3).
Synthesis of azide derivatized dicarboxylate ligand.
We attached 4-Azidobenzoic succinimidyl ester (2.7) to L-glutamate di-tert-butyl ester
hydrochloride (3.6) in the presence triethylamine and DMF. The azido derivatized amino
acid product (4.2) was furnished in good yield. Later, the Boc-protecting group was
removed in presence of 20% TFA in DCM to yield azide derivatized dicarboxylate 4.3
(Scheme 4.1).
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Retrosynthetic analysis
After completing the synthesis of the azide derivatized dicarboxylate ligand (scheme
4.1), and photocaged dox conjugate (scheme 2.4), we planned to assemble the desired
photocaged drug-ligand conjugates using click chemistry as shown below.

Peptide coupling
reaction

Click
chemistry

Fig. 4.3: Strategy for synthesis of photocaged drug-ligand conjugate

136

Scheme 4.1: Schematic synthesis of photocaged drug-dicarboxylate ligand conjugate:
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4. 3 Syntheses of photocaged drug- carboxylate ligand conjugate
For the syntheses of the drug conjugate, we used both azide derivatized ligand 4.3 and
coupled it with Dox alkyne 2.13 using click chemistry. The contents were solubilized in
1:1 DMSO and water in presence of CuSO4, sodium ascorbate and TBTA which
eventually yielded photocaged drug-dicarboxylic conjugate, 4.4.
colored solid 3.13 is shown in Fig. 3.4.

FT-MS of the red
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4.4 Discussion
The aim of this project is to synthesize a drug conjugate that could be grafted onto a
previously designed UCNP. For this purpose, we used boc-protected glutamic acid and
coupled it to 4-azidobenzoic succinimidyl ester to generate azide derivatized boc
glutamate. Later, we coupled photocaged doxorubicin with an azide unit via click
chemistry to yield photocaged drug-dicarboxylate ligand. Later, our collaborators will use
this drug conjugate to be attached to UCNP and demonstrate NIR mediated photorelease
of the drug from the conjugate.
Future studies:
The ultimate aim of this project is to extend the usage of the photocaged drug delivery
toward in vivo studies. The current established method is dependent on UV light, which
does not penetrate deep into tissues. Hence, in this project we aim to demonstrate drug
release using UCNPs that generate UV when irradiated with NIR and test it initially in
vitro and later in vivo.
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4.5. Experimental Section
General
All reagents were purchased from Sigma-Aldrich, Fisher Scientific, TCI or Chem-impex
unless otherwise specified and were used as received. All reactions were carried out in
oven dried glassware and under Ar or N2 atmosphere. The reactions were carried out in
foil-wrapped flasks, protected from light. Flash chromatography was performed using
Flash Silica Gel (32-63μ). 1H NMR/

13

C spectra were recorded on 400 MHz Bruker

AVANCE instruments. HPLC purification was carried out using a Shimadzu Prominence
system using Vydac (218TP C18 5μ) column using 0.1% TFA in acetonitrile and water
as eluents and was monitored at λmax = 480 nm. M/S data was collected using Micromass
MALDI-R/TOF (positive modes) unless mentioned.
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4.6 Chemical Synthesis
Synthesis of Photocaged doxorubicin has already been described in the experimental
section of Chapter 2.
Synthesis of di-tert-butyl 2-(4-azidobenzamido)pentanedioate (4.2):

To a stirred solution of 6-azidobenzoic-OSu (2.8) (261 mg, 1 mmol, 1 eq.) in DMF (10
mL) was added L-glutamate di-tert-butyl ester hydrochloride (338 mg, 1.3 mmol, 1.3
eq.). and triethylamine (278 μL, 2 mmol, 2 eq.). The reaction was allowed to stir in the
dark for 12 h. After this, DMF was removed in vacuo and the crude reaction mixture was
diluted with CH2Cl2 and washed with 1 N aq. HCl. and then with brine. The organic layer
was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to
give a pale white solid, which was further purified via flash chromatography using a
mixture of ethyl acetate and hexanes (1:1) to yield 320 mg (85%) of 4.2.
1

H NMR (400 MHz, CDCl3) δ = 7.83 (2H, m, Ar-H), 7.07 (2H, m, Ar-H), 7.00 (1H, m,),

4.65 (1h, , -CH-), 2.01-2.26 (2H, m, -CH2-), 2.28-2.47 (2H, m -CH2-), 1.49 (9H, s, Boc),
1.42 ( 9H, s, Boc ).
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13

C NMR (100 MHz, CDCl3) δ = 172.73, 171.32, 166.06, 143.51, 130.44, 128.96,

118.96, 82.47, 80.96, 53.03, 31.71, 28.07, 28.04, 27.34,
Synthesis of 2-(4-azidobenzamido) pentanedioic acid (4.3):

100 mg of 4.2 was solubilized in a solution of 20% TFA in DCM (10ml) and stirred for
~10 h in a foil-wrapped flask. The solvents in the reaction mixture were removed in
vacuo. To the pale colored oily solid, about cold ether (25 mL) was added. The
suspension was vortexed for about 5 minutes and then centrifuged in a 50 mL of falcon
tube. This procedure was a second time giving yield the product as a brown colored oil
70% yield (50 mg).
1

H NMR (400 MHz, CDCl3)

12.38 (2H, brs,-COOHx2), 8.62 (1H, d, J = 7.6 Hz, CONH), 7.95 (2H, m, Ar-H), 7.22
(2H, m, Ar-H), 4.93 (m, 1H,-CH-), 2.36 (2H, 7.2 Hz, -CH2-), 2.09 (1H, m, -CH2-), 1.96
(1H, m, -CH2-).
13

C NMR (100 MHz, CDCl3)

δ = 173.78, 173.30, 165.59, 142.46, 130.44, 129.34, 118.82, 64.86, 51.95, 30.37, 25.90,
15.10
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Synthesis of 2-(4-azidobenzamido) pentanedioic acid (4.4):

Compounds 2.13 (20 mg, 0.022 mmol, 1eq.) and 4.3 (13 mg, 0.044 mmol, 2 eq.) were
stirred in 1:1 mixture of water and DMSO (2 mL each). 40 μL (0.4 mg, 0.002 mmol, 0.1
eq.) of a freshly prepared aqueous solution of sodium ascorbate (10 mg/mL) was added to
the reaction, followed by 4 μL (0.05 mg, 0.01 eq., 0.0002 mmol) of freshly prepared
aqueous solution of copper (II) sulfate pentahydrate (12.5 mg/ mL), and finally 1.1 mg
(0.1 eq., 0.002 mmol) of TBTA (Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine) was
added. The red colored heterogenous mixture was stirred vigorously until the reaction
was completed (~24h) as judged by TLC (1: 4 CH3OH/CHCl3). The reaction mixture was
concentrated in vacuo, filtered and the resulting solution was purified on RP-HPLC using
isocratic elution of 20 % organic eluent (0.1 % TFA in acetonitrile) for 5 minutes and
then increasing the acetonitrile fraction in gradient fashion from 20 % to 100% over 30
minutes at 10 ml/min. The fractions (~10 mL each) were collected into tubes containing
1000 μL of ammonium bicarbonate (6 mg/ mL) solution to quench the TFA. The two
diastereomers eluted between 20 and 22 min. The fractions containing the diastereomers
were evaporated leaving a red solid in ammonium bicarbonate.
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Photocaged drug carboxylate ligand
conjugate
Dox-propargylamine

Dox-propargylamine

Fig. 4.5: HPLC chromatogram to show the formation of new diastereomeric peaks
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CHAPTER 5.

A NEW, HIGHLY WATER-SOLUBLE, FLUORESCENT TURN-ON
CHEMODOSIMETER FOR DIRECT MEASUREMENT OF HYDROGEN
SULFIDE IN BIOLOGICAL FLUIDS

Matthew C. T. Hartman and M. Michael Dcona

This chapter in part was published under the same title.
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Abstract:
A new reaction-based fluorescent reporter for H2S has been developed based on 8aminopyrene-1, 3, 6-trisulfonate. This chapter describes a probe that has high selectivity
for H2S over other ions and thiols, and can detect H2S directly in serum without additives.
5. 1. Introduction
Although previously considered as a toxic gas, hydrogen sulfide has recently been
discovered to be an important gaseous signaling compound. H2S has been shown to be
involved in a diverse and ever expanding array of biochemical processes such as
inflammation, control of blood pressure, neurotransmission, and ischemia reperfusion.1–9
Several methods to determine the H2S concentration in biological samples have been
developed including those based on colorimetric,10,11 electrochemical,12,13 and other
approaches.14,

15

However, these methods often require extensive sample processing

before measurement, complicating their use.

Because of the potential ability to monitor H2S in situ, we and other groups have very
recently become interested in investigating the use of fluorescence-turn-on reporters for
H2S.16–29 One successful strategy pioneered by the Chang group19 has been to use the
ability of H2S to rapidly and selectively reduce azides to amines as a means to turn on
fluorescence.22,23,26,29 Conveniently, many fluorescent molecules are quenched when their
aryl amino groups are converted to the corresponding azides.29–31 In this chapter, our
effort has focused on an azido analog of 8-aminopyrene-1,3,6-trisulfonic acid (APTS)
and its use as an H2S chemodosimeter (Fig. 5.1). As compared to other profluorescent
molecules used for H2S sensing, 8-azidopyrene-1, 3, 6-trisulfonic acid (N3-PTS) has the
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advantages of high selectivity vs. other ions and thiols, and extremely high water
solubility. These features enable analysis of H2S concentrations in biological samples
without prior sample processing.

Fig: 5.1: N3-PTS, a highly water soluble chemodosimeter for measurement of H2S in biological
fluids
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5. 2. Design and chemical synthesis of the probe

Our general strategy for detection of H2S in biological samples was based on usage of a
water soluble molecule that carried an azide functional group, which renders it nonfluorescent, and when converted to the amine functional group in presence of H2S, the
fluorescence of molecule is restored (Fig. 5.1). To achieve this goal, we converted the
highly water soluble and fluorescent dye, APTS, to the azido derivative, N3-PTS.

Chemical Synthesis

The chemical synthesis of the chemodosimeter probe proceeded according to Scheme 1.
We first prepared APTS 5.2 from amino pyrene 5.1 (TCI America) by treating it with
oleum in the presence of sodium sulfate 34. This reaction mixture was purified using flash
chromatography and desalted using a Biogel-P2 column, eluting in 50 mM ammonium
bicarbonate buffer. APTS was treated with sodium nitrite in the presence of sulfuric acid
to form the diazonium salt of pyrene trisulfonic acid, which was directly converted to N 3PTS 5.3, with sodium azide. The resulting product was readily purified using size
exclusion chromatography with Bio-Gel P-2 using ammonium bicarbonate buffer. The
ammonium salt of N3-PTS is highly soluble in water at concentrations >100 mM.
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Scheme to synthesize H2S detection probe

Scheme
5.1: Synthesis of N3-PTS from Aminopyrene
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5. 3. Spectral Characteristics:

The absorption spectrum of N3-PTS shows a blue-shift relative to APTS (Fig. 5.2 A) with
peaks at 382 and 403 nm, vs. 427 nm for APTS. As seen with other fluorophores,19,22,30,31
the presence of the azide dramatically quenches the fluorescence (Fig. 5.2 B) of N3-PTS.

Relative quantum yield measurements:

For the measurement of quantum yield, we plotted absorbance vs. integrated fluorescence
λex=425 nm for solutions of APTS and N3PTS. A comparison of the slopes of the lines
shows that at 425 nm excitation, the quantum yield of N3-PTS is 24-fold lower than
APTS (Fig. 5.3).
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Fig. 5.2: Spectral parameters of APTS and N3-PTS.
(A) The absorbance spectral scans of N3-PTS (red) and APTS (blue), both at 50 µM, are
shown. (B) The fluorescence spectral emission scans (λex = 435 nm) of N3-PTS (red) and
APTS (blue), both at 5 μM, are shown.
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Fig. 5.3: Relative quantum yield measurement of APTS and N3-PTS. Fluorescence
spectra were obtained with λex = 425 nm.
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Absorbance vs. Concentration plots
In order to determine the wavelength for maximum fluorescence enhancement of APTS
vs. N3PTS, we measured the extinction coefficients at 382, 424, 436, and 451 nm (see
Fig. 5.3 and Table 5.1). 435 nm showed the maximal 42-fold increase in extinction
coefficient, and this wavelength was therefore used to maximize fluorescent enhancement
in the subsequent studies.
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Fig. 5.4: Absorbance vs. concentration plots of APTS and N3-PTS at various wavelengths
in water.
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Table 5.1: Absorbance parameters were calculated using Beer’s law.
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5. 4. Fluorescence enhancement is dependent on H2S concentration
We expected that H2S-mediated azide reduction would convert N3-PTS to APTS, with a
corresponding enhancement in fluorescence. A solution of 50 µM NaHS was prepared
and added to 100 µM N3-PTS in phosphate buffer. The reaction was monitored by
fluorescence (Fig. 5.5) and was compared with the same reaction lacking NaHS. A timedependent large increase in fluorescence was observed in the solution containing NaHS.
After 90 minutes a 7-fold fluorescence enhancement was observed.
Time Course of H2S reactions at different concentrations:
We then monitored the concentration dependence of the H2S reaction with N3-PTS.
Solutions of NaHS (0-100 M) were prepared and mixed with N3-PTS.

We then

monitored the reaction in a fluorescence spectrometer at 505 nm at λex = 435 nm. We
found that the fluorescence intensity of all solutions increased over time. The amount of
the increase is proportional to the NaHS concentration (Fig. 5.6).
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Fig. 5.5: Enhancement in fluorescence of N3-PTS solutions in the presence of H2S. A
solution of 100 μM N3-PTS and either 50 µM NaHS or water was incubated in phosphate
buffer (pH 7.8) at room temperature for various times. Fluorescence emission scans (λex
= 435 nm) were taken every 5 minutes.
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Fig. 5.6: Reaction of H2S at various concentrations with N3-PTS. The reaction was
monitored at 505 nm (λex = 435 nm), and readings were taken at 1 minute intervals

160

5. 5. Selectivity of chemodosimeter towards H2S
We then proceeded to test the selectivity of our potential H2S chemodosimeter versus a
collection of several common anions, reactive oxygen and nitrogen species, and thiols
(Fig. 5.7). Significant fluorescence enhancement was observed only in the presence of 50
µM HS−. The fluorescence signal of other ions (OAc−, N3−, HCO3−, Cl−, OH−, NO2−,
SO42−, SO32−, S2O32−), thiols (glutathione and cysteine), or reactive oxygen and nitrogen
species (Fig. 5.8) gave little to no fluorescence enhancement when tested at 1 mM, a 20fold higher concentration. Thus, N3-PTS shows excellent selectivity for aqueous
hydrogen sulfide in the presence of other ions and thiols encountered in biological
environments.
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Fig. 5.7: Comparison of the fluorescence of N3-PTS after incubation in 50 mM phosphate
buffer (pH 7.8) along with NaHS (50 mM) or NaOAc,NaN3, NaHCO3, NaCl, NaOH,
NaNO2, Na2SO4, Na2SO3, Na2S2O4, reduced glutathione or L-cysteine hydrochloride (all
1 M). Fluorescence emission (λex= 435 nm) was measured after 90 min.
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Fig. 5.8: Comparison of the fluorescence of N3-PTS after incubation in 50 mM phosphate
buffer (pH 7.8) along with with NaHS (50 μM) or NaOCl, Sodium Diethylamine
NONOate, or tBuOOH (all 1 mM). Fluorescence emission (λex = 435 nm) was measured
after 90 min.
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In order to use N3-PTS to quantify HS− in biological samples it is desirable that the
fluorescence be linearly related to the sulfide concentration. Indeed, treatment of N3-PTS
(100 µM) with several different concentrations of HS− led to the expected linear
relationship (Fig. 5.9). HS− was easily quantifiable by fluorescence when its
concentration was between 2 and 100 µM.
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Fig. 5.9: Plot of H2S concentration vs. N3-PTS fluorescence. N3-PTS (100 mM) and H2S
(0–100 mM) were incubated in 50 mM phosphate buffer pH 7.8 at room temperature for
90 minutes. Error bars denote one standard deviation from the mean of three experiments.
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5. 6. Detection of fluorescence in biological samples
With the linearity and selectivity studies completed, we turned our attention H 2S
detection in biological milieu. First, we investigated the extent to which APTS
fluorescence was quenched in fetal bovine serum (FBS) vs. standard phosphate buffer.
FBS showed little, if any, quenching (Fig. 5.10) suggesting that the measurement of H2S
could be accomplished directly in the media without prior removal of proteins. Moreover,
the high water solubility of N3-PTS could in principle allow measurement of fluorescence
without addition of any organic co-solvents or detergents. We then titrated NaHS into
FBS containing N3-PTS. After 90 minutes, the fluorescence was measured showing good
linear dependence (Fig. 5.11).The point at which the fluorescence was >2-fold above
background was 9 µM.
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Fig. 5.10: Comparison of fluorescence intensity (λex = 450 nm) of APTS at various
concentrations in either phosphate buffer or Serum (FBS).
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Fig. 5.11: Linear relationship between H2S concentration and N3-PTS fluorescence in
90% fetal bovine serum (FBS). N3-PTS (100 mM) and H2S (0–100 mM) were incubated
in FBS at room temperature for 90 minutes. Error bars denote one standard deviation
from the mean of three experiments.
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Using N3-PTS, we can measure the H2S concentration in FBS in the range of 10–100 µM.
This concentration range corresponds exactly with the range of H2S concentrations found
in human blood.32 We also observed that the fluorescence enhancement in FBS at the
same concentration of NaHS was diminished compared to phosphate buffer. This reduced
sensitivity was presumably due to the quenching of the added HS− with serum
electrophiles.33 We surmise, therefore, that derivatizing N3-PTS to maximize its reaction
rate with H2S will lead to enhanced sensitivity in serum.

5. 7. Summary

In summary we have developed a new chemodosimeter for hydrogen sulfide based on
H2S conversion of profluorescent N3-PTS to APTS. N3-PTS can be prepared in good
yield in a single step from commercially available APTS. N3-PTS shows very high
selectivity for H2S and is extremely water soluble. These two properties have allowed us
to measure H2S levels in serum directly without any processing of the sample or addition
of detergents or co-solvents. The compatibility of N3-PTS with aqueous solutions
distinguishes it from other fluorescent methods for H2S detection and makes it well suited
for in situ analysis of H2S levels in a variety of biological fluids.
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5. 8. Experimental section
I. General
All reagents were purchased from Sigma-Aldrich, Fisher Scientific or TCI America
unless otherwise specified and were used as received. Reactions were carried out in foilwrapped flasks protected from light. Purification of the intermediates were carried out
either using flash chromatography using Flash Silica Gel (32-63μ) or using a Biogel P-2
column (1.5 x 80 cm), eluted with 50 mM aq. NH4OAc.
Fluorescence spectra were recorded with a Cary Eclipse Fluorescence Spectrophotometer
(Agilent Technologies, Inc.) at ambient temperature and under ambient atmosphere.
Samples were contained in black, flat-bottomed 96 well plates. The PMT setting was 600
V for all readings. For samples containing H2S, the plate was sealed immediately after
addition of a NaHS solution of the appropriate concentration. Fluorescence readings were
taken either with the seal removed or with optically clear sealing tape intact. Readings
taken in FBS had a final FBS concentration of 90%, with the remaining 10% aqueous
solution containing the fluorophore and NaHS.
UV-Vis Absorbance spectra were recorded on a Hewlett Packard 8453 UV-visible
Spectroscopy Systems instrument in disposable UV cuvettes (BrandTech) (Quantum
yield measurements) or using a Nano-Drop 2000 spectrophotometer (UV-Vis absorbance
profile and Beer’s Law readings). IR readings were taken on a Nicolet Avatar 360 FT-IR.
1

H NMR spectra were recorded on a Bruker 400 MHz NMR and were calibrated to the

D2O solvent peak which was set to 4.79 ppm. 13C NMR spectra were recorded on a 600
MHz Bruker Advance III instrument using the attached proton test.

13

C NMR spectra in
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D2O were calibrated using methanol as an internal standard set to 49.50 ppm. Even using
this high field instrument there were indistinguishable

13

C peaks for N3-PTS. Observed

peaks were reported. Mass spectra were acquired on a LTQ-Orbitrap Velos from Thermo
Electron Corporation operating in negative ion mode.
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5.9. Chemical synthesis
Synthesis of Aminopyrene trisulfonic acid trisodium salt (APTS), (5.2):

A dry round bottom flask with Na2SO4 (1.13 g, 8 mmol, 4 eq.) and conc. H2SO4 (5 mL)
was arranged for reflux and fitted with a drying tube (filled with drierite and NaOH
pellets). Aminopyrene (434 mg, 2 mmol, 1 eq.) was added along with fuming sulfuric
acid (20%, 6 mL). The mixture was stirred for ~1.5 days at 600C and monitored using
TLC (NH4OH: IPA, 1:2). After the completion of the reaction, the mixture was quenched
using 50% NaOH and the pH is brought up to about 7. Later the solvents were removed
in vacuo and the mixture was diluted with methanol, filtered to remove salts and purified
using flash column using 1: 2 ratio of NH4OH and Isopropyl alcohol leaving 1.0 g of a
yellow solid.

534 mg of this solid was purified in two portions using Biogel P-2

chromatography (1.5 x 90 cm column, eluting with 50 mM NH4HCO3 at 0.15 mL/min).
Fractions containing the product were combined and lyophilized leaving 174.2 mg of an
orange solid.
Yield: ~1gm (98% yield) sodium salt; 174 mg from 534 mg of sodium salt (33 % yield)
1

H NMR (D2O, 400 MHz): 9.29 (s, 1H), 9.14 (d, 1H, J = 16 Hz), 9.035 (d, 1H, J = 12

Hz), 8.90 (d, 1H, J = 12 Hz), 8.42 (d, 1H, J = 16 Hz), 8.17( s, 1H).
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Triammonium 8-azidopyrene-1, 3, 6-trisulfonate (N3-PTS), (5.3):

A solution of triammonium 8- aminopyrene-1,3,6-trisulfonate (100 mg, 0.22 mmol) was
dissolved in ice cold 3.6 N H2SO4 (500 μL) in a foil wrapped flask on ice. An aqueous
solution of 0.66 M NaNO2 (1 mL, 3 eq) was added dropwise over 10 min. A solution of
ice cold 1.1 M sodium azide (1.2 mL, 6 eq) was added dropwise over 10 min. The
reaction was stirred on ice for an additional 40 min and was quenched with 0.5 mL
concentrated NH4OH. The solution was concentrated via rotary evaporation and purified
using a Biogel P-2 column (1.5 x 80 cm), eluting with 50 mM aq NH4HCO3 at a flow rate
of 0.15 mL/min. The fractions containing the product were combined and lyophilized
giving a fluffy yellow powder (79 mg, 75%).
IR νmax/cm-1 (3435m, 3180s, 3199s, 2870m, 2113s (N3 stretch), 1625w, 1416s, 1161s,
1115s, 1036s, 998s, 733m, 653s, 604s).
1

H NMR (400 MHz, D2O): δ = 9.23 (s, 1H), 9.21 (d, 1H, J = 9.8 Hz), 9.11 (d, 1H, J = 9.8

Hz), 9.10 (d, 1H, J = 9.7 Hz), 8.73 (d, 1H, J = 9.7 Hz), 8.64 (s, 1H).
13

C NMR (150 MHz, D2O): δ = 139.05 (q), 135.90 (q), 130.43 (q), 129.71 (q), 127.73 (C-

H), 125.68 (C-H), 125.51 (q), 125.20 (C-H), 124.87 (C-H), 124.76 (C-H), 123.44 (q),
123.40 (q), 116.60 (C-H).
HRMS (ESI) C16H7N3O9S3 calculated [M – 2H] 2- = 240.4677; Observed = 240.4678.
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